

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/00, 15/12		(11) International Publication Number: WO 99/32614	
		(43) International Publication Date: 1 July 1999 (01.07.99)	
(21) International Application Number: PCT/US98/27140	(72) Inventors: JACOBS, Kenneth; 151 Beaumont Avenue, Newton, MA 02160 (US); MCCOY, John, M.; 56 Howard Street, Reading, MA 01867 (US); LAVALLIE, Edward, R.; 113 Ann Lee Road, Harvard, MA 01451 (US); COLLINS-RACIE, Lisa, A.; 124 School Street, Acton, MA 01720 (US); EVANS, Cheryl; 307 Broughton Drive, Beverly, MA 01915 (US); MERBERG, David; 2 Orchard Drive, Acton, MA 01720 (US); TREACY, Maurice; 93 Walcott Road, Chestnut Hill, MA 02167 (US); ACOSTINO, Michael, J.; 26 Wolcott Avenue, Andover, MA 01810 (US); STEININGER, Robert, J., II; 100 Reed Street, Cambridge, MA 02140 (US); WONG, Gordon, G.; 239 Clark Road, Brookline, MA 02146 (US); CLARK, Hilary, F.; 146 Webster Avenue #2, Cambridge, MA 02141 (US); FECHTEL, Kim; 46 Marion Road, Arlington, MA 02174 (US).		
(22) International Filing Date: 18 December 1998 (18.12.98)	(74) Agent: SPRUNGER, Suzanne, A.; Genetics Institute, Inc., 87 CambridgePark Drive, Cambridge, MA 02140 (US).		
(30) Priority Data: 60/068,379 09/212,843	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, NG, SN, TD, TO).		
(71) Applicant: GENETICS INSTITUTE, INC. [US/US]; 87 Cam- bridgePark Drive, Cambridge, MA 02140 (US).	Published With international search report.		
(54) Title: SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM			
(57) Abstract Novel polynucleotides and the proteins encoded thereby are disclosed.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	UZ	Uzbekistan
CA	Canada	IT	Italy	NE	Niger	US	United States of America
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	St. Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SE	Sweden		
DE	Germany	LK	Sri Lanka	SG	Singapore		
DK	Denmark	LR	Liberia				
EE	Estonia						

SECRETED PROTEINS AND POLYNUCLEOTIDES ENCODING THEM

5 This application is a continuation-in-part of provisional application Ser. No. 60/066,369, filed December 20, 1997, which is incorporated by reference herein.

FIELD OF THE INVENTION

10 The present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.

BACKGROUND OF THE INVENTION

15 Technology aimed at the discovery of protein factors (including e.g., cytokines, such as lymphokines, interferons, CSFs and interleukins) has matured rapidly over the past decade. The now routine hybridization cloning and expression cloning techniques clone novel polynucleotides "directly" in the sense that they rely on information directly related to the discovered protein (i.e., partial DNA/amino acid sequence of the protein in the case of hybridization cloning; activity of the protein in the case of expression cloning). More recent "indirect" cloning techniques such as signal sequence cloning, which isolates DNA sequences based on the presence of a now well-recognized secretory leader sequence motif, as well as various PCR-based or low stringency hybridization cloning techniques, have advanced the state of the art by making available large numbers of DNA/amino acid sequences for proteins that are known to have biological activity by virtue of their secreted nature in the case of leader sequence cloning, or by virtue of the cell or tissue source in the case of PCR-based techniques. It is to these proteins and the polynucleotides encoding them that the present invention is directed.

SUMMARY OF THE INVENTION

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- 5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 179 to nucleotide 4285;
- (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone am728_60 deposited under accession number ATCC 98621;
- 10 (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone am728_60 deposited under accession number ATCC 98621;
- (e) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone am728_60 deposited under accession number ATCC 98621;
- 15 (f) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone am728_60 deposited under accession number ATCC 98621;
- (g) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
- 20 (h) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;
- (i) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above;
- 25 (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above; and
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h).
- 30 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:1 from nucleotide 179 to nucleotide 4285; the nucleotide sequence of the full-length protein coding sequence of clone am728_60 deposited under accession number ATCC 98621; or the nucleotide sequence of a mature protein coding sequence of clone am728_60 deposited under accession number ATCC 98621. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert

of clone am728_60 deposited under accession number ATCC 98621. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 679 to amino acid 688 of SEQ ID NO:2.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ

10 ID NO:1.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:1; and
 - (ab) the nucleotide sequence of the cDNA insert of clone am728_60 deposited under accession number ATCC 98621;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:1; and
 - (bb) the nucleotide sequence of the cDNA insert of clone am728_60 deposited under accession number ATCC 98621;
 - (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C;
 - (iii) amplifying human DNA sequences; and

- (iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 179 to nucleotide 4285, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 179 to nucleotide 4285, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 179 to nucleotide 4285.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
- (b) fragments of the amino acid sequence of SEQ ID NO:2, each fragment comprising eight consecutive amino acids of SEQ ID NO:2; and
- (c) the amino acid sequence encoded by the cDNA insert of clone am728_60 deposited under accession number ATCC 98621;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:2. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 679 to amino acid 688 of SEQ ID NO:2.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 108 to nucleotide 254;

- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 225 to nucleotide 254;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone b377_1 deposited under accession number ATCC 98621;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone b377_1 deposited under accession number ATCC 98621;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone b377_1 deposited under accession number ATCC 98621;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone b377_1 deposited under accession number ATCC 98621;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:3 from nucleotide 108 to nucleotide 254; the nucleotide sequence of SEQ ID NO:3 from nucleotide 225 to nucleotide 254; the nucleotide sequence of the full-length protein coding sequence of clone b377_1 deposited under accession number ATCC 98621; or the nucleotide sequence of a mature protein coding sequence of clone b377_1 deposited under accession number ATCC 98621. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone b377_1 deposited under accession number ATCC 98621. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most

preferably thirty) consecutive amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 19 to amino acid 28 of SEQ ID NO:4.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:3.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and

(ab) the nucleotide sequence of the cDNA insert of clone b377_1 deposited under accession number ATCC 98621;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and

(bb) the nucleotide sequence of the cDNA insert of clone b377_1 deposited under accession number ATCC 98621;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 108 to nucleotide 254, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 108 to nucleotide 254, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 108 to nucleotide 254. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 225 to nucleotide 254, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 225 to nucleotide 254, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 225 to nucleotide 254.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:4;
 - (b) fragments of the amino acid sequence of SEQ ID NO:4, each fragment comprising eight consecutive amino acids of SEQ ID NO:4; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone bf377_1 deposited under accession number ATCC 98621;
- the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:4. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 19 to amino acid 28 of SEQ ID NO:4.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 426 to nucleotide 569;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 546 to nucleotide 569;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cw354_1 deposited under accession number ATCC 98621;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cw354_1 deposited under accession number ATCC 98621;
 - (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cw354_1 deposited under accession number ATCC 98621;
 - (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone cw354_1 deposited under accession number ATCC 98621;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:6;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;
 - (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; and
 - (l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).
- Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:5 from nucleotide 426 to nucleotide 569; the nucleotide sequence of SEQ ID NO:5 from nucleotide 546 to nucleotide 569; the nucleotide sequence of the full-length protein coding sequence of clone cw354_1 deposited under accession number ATCC 98621; or the nucleotide sequence of a mature protein coding sequence of clone cw354_1 deposited under accession number ATCC 98621. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert

of clone cw354_1 deposited under accession number ATCC 98621. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 19 to amino acid 28 of SEQ ID NO:6.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ

10 ID NO:5.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:
 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(ab) the nucleotide sequence of the cDNA insert of clone cw354_1 deposited under accession number ATCC 98621;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

25 and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and

(bb) the nucleotide sequence of the cDNA insert of clone cw354_1 deposited under accession number ATCC 98621;

30

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

5 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5. Also preferably the polynucleotide isolated

10

according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 426 to nucleotide 569, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 426 to nucleotide 569, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 426 to nucleotide 569. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 546 to nucleotide 569, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 546 to nucleotide 569, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 546 to nucleotide 569.

15

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:6;

25

(b) fragments of the amino acid sequence of SEQ ID NO:6, each fragment comprising eight consecutive amino acids of SEQ ID NO:6; and

(c) the amino acid sequence encoded by the cDNA insert of clone cw354_1 deposited under accession number ATCC 98621;

30

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:6. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of

WO 99/32614	PCT/US98/27140	WO 99/32614	PCT/US98/27140
SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 19 to amino acid 28 of SEQ ID NO:6. In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:		sequence of clone nm134_4 deposited under accession number ATCC 98621; or the nucleotide sequence of a mature protein coding sequence of clone nm134_4 deposited under accession number ATCC 98621. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone nm134_4 deposited under accession number ATCC 98621. In yet other preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8 from amino acid 104 to amino acid 163. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 118 to amino acid 127 of SEQ ID NO:8.	
5 (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;	(a) a process comprising the steps of:		
(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 151 to nucleotide 891;	(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:		
(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 595 to nucleotide 891;	(aa) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and		
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone nm134_4 deposited under accession number ATCC 98621;	(ab) the nucleotide sequence of the cDNA insert of clone nm134_4 deposited under accession number ATCC 98621;		
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone nm134_4 deposited under accession number ATCC 98621;	(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C; and		
(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone nm134_4 deposited under accession number ATCC 98621;	(iii) isolating the DNA polynucleotides detected with the probe(s);		
(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone nm134_4 deposited under accession number ATCC 98621;	and		
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;	(b) a process comprising the steps of:		
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:8;			
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;			
(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; and			
(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).			
Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7 from nucleotide 151 to nucleotide 891; the nucleotide sequence of SEQ ID NO:7 from nucleotide 595 to nucleotide 891; the nucleotide sequence of the full-length protein coding			

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and

(bb) the nucleotide sequence of the cDNA insert of clone nm134_4 deposited under accession number ATCC 98621;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

15 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 151 to nucleotide 891, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 151 to nucleotide 891, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 151 to nucleotide 891. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 595 to nucleotide 891, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 595 to nucleotide 891, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 595 to nucleotide 891.

25 In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:8;

(b) the amino acid sequence of SEQ ID NO:8 from amino acid 104 to amino acid 163;

(c) fragments of the amino acid sequence of SEQ ID NO:8, each fragment comprising eight consecutive amino acids of SEQ ID NO:8; and

(d) the amino acid sequence encoded by the cDNA insert of clone nm134_4 deposited under accession number ATCC 98621;

5 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:8 or the amino acid sequence of SEQ ID NO:8 from amino acid 104 to amino acid 163. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 118 to amino acid 127 of SEQ ID NO:8.

10 In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 1909 to nucleotide 2127;

20 (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 2074 to nucleotide 2127;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yb11_1 deposited under accession number ATCC 98621;

25 (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yb11_1 deposited under accession number ATCC 98621;

(f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yb11_1 deposited under accession number ATCC 98621;

30 (g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yb11_1 deposited under accession number ATCC 98621;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:10;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

(k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

10 Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9 from nucleotide 1909 to nucleotide 2127; the nucleotide sequence of SEQ ID NO:9 from nucleotide 2074 to nucleotide 2127; the nucleotide sequence of the full-length protein coding sequence of clone yb11_1 deposited under accession number ATCC 98621; or the nucleotide sequence of a mature protein coding sequence of clone yb11_1 deposited under accession number ATCC 98621. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yb11_1 deposited under accession number ATCC 98621. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 31 to amino acid 40 of SEQ ID NO:10.

25 Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:9.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

(a) a process comprising the steps of:

30 (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and

(ab) the nucleotide sequence of the cDNA insert of clone yb11_1 deposited under accession number ATCC 98621;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and

(bb) the nucleotide sequence of the cDNA insert of clone yb11_1 deposited under accession number ATCC 98621;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

20 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9. Also preferably the polynucleotide isolated

25 according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 1909 to nucleotide 2127, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 1909 to nucleotide 2127, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 1909 to

30 nucleotide 2127. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 2074 to nucleotide 2127, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from

nucleotide 2074 to nucleotide 2127, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 2074 to nucleotide 2127.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:10;
- (b) fragments of the amino acid sequence of SEQ ID NO:10, each fragment comprising eight consecutive amino acids of SEQ ID NO:10; and
- (c) the amino acid sequence encoded by the cDNA insert of clone yb11_1 deposited under accession number ATCC 98621;

the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:10. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:10, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 31 to amino acid 40 of SEQ ID NO:10.

In one embodiment, the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 1077 to nucleotide 1733;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 1158 to nucleotide 1733;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yc2_1 deposited under accession number ATCC 98621;

- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yc2_1 deposited under accession number ATCC 98621;
- (f) a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone yc2_1 deposited under accession number ATCC 98621;

(g) a polynucleotide encoding a mature protein encoded by the cDNA insert of clone yc2_1 deposited under accession number ATCC 98621;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;

- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:12;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above;

- (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above; and

(l) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(l).

Preferably, such polynucleotide comprises the nucleotide sequence of SEQ ID NO:11 from nucleotide 1077 to nucleotide 1733; the nucleotide sequence of SEQ ID NO:11 from nucleotide 1158 to nucleotide 1733; the nucleotide sequence of the full-length protein coding sequence of clone yc2_1 deposited under accession number ATCC 98621; or the nucleotide sequence of a mature protein coding sequence of clone yc2_1 deposited under accession number ATCC 98621. In other preferred embodiments, the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone yc2_1 deposited under accession number ATCC 98621. In further preferred embodiments, the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 104 to amino acid 113 of SEQ ID NO:12.

Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO:11.

Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:

- (a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and

(ab) the nucleotide sequence of the cDNA insert of clone yc2_1 deposited under accession number ATCC 98621;

(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C; and

(iii) isolating the DNA polynucleotides detected with the probe(s);

and

(b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and

(bb) the nucleotide sequence of the cDNA insert of clone yc2_1 deposited under accession number ATCC 98621;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii).

25 Preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 1077 to nucleotide 1733, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 1077 to nucleotide 1733, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide

1077 to nucleotide 1733. Also preferably the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 1158 to nucleotide 1733, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 1158 to nucleotide 1733, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 1158 to nucleotide 1733.

In other embodiments, the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:

10 (a) the amino acid sequence of SEQ ID NO:12;

(b) fragments of the amino acid sequence of SEQ ID NO:12, each fragment comprising eight consecutive amino acids of SEQ ID NO:12; and

(c) the amino acid sequence encoded by the cDNA insert of clone yc2_1 deposited under accession number ATCC 98621;

15 the protein being substantially free from other mammalian proteins. Preferably such protein comprises the amino acid sequence of SEQ ID NO:12. In further preferred embodiments, the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) consecutive amino acids of SEQ ID NO:12, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 104 to amino acid 113 of SEQ ID NO:12.

20 In certain preferred embodiments, the polynucleotide is operably linked to an expression control sequence. The invention also provides a host cell, including bacterial, yeast, insect and mammalian cells, transformed with such polynucleotide compositions. Also provided by the present invention are organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein.

Processes are also provided for producing a protein, which comprise:

30 (a) growing a culture of the host cell transformed with such polynucleotide compositions in a suitable culture medium; and

(b) purifying the protein from the culture.

The protein produced according to such methods is also provided by the present invention.

Protein compositions of the present invention may further comprise a pharmaceutically acceptable carrier. Compositions comprising an antibody which specifically reacts with such protein are also provided by the present invention.

Methods are also provided for preventing, treating or ameliorating a medical condition which comprises administering to a mammalian subject a therapeutically effective amount of a composition comprising a protein of the present invention and a pharmaceutically acceptable carrier.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B are schematic representations of the pED6 and pNOT3 vectors, respectively, used for deposit of clones disclosed herein.

DETAILED DESCRIPTION

ISOLATED PROTEINS AND POLYNUCLEOTIDES

Nucleotide and amino acid sequences, as presently determined, are reported below for each clone and protein disclosed in the present application. The nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods. The predicted amino acid sequence (both full-length and mature forms) can then be determined from such nucleotide sequence. The amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence. For each disclosed protein applicants have identified what they have determined to be the reading frame best identifiable with sequence information available at the time of filing.

As used herein a "secreted" protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence. "Secreted" proteins include without limitation proteins secreted wholly (e.g., soluble proteins) or partially (e.g., receptors) from the cell in which they are expressed. "Secreted" proteins also include without limitation proteins which are transported across the membrane of the endoplasmic reticulum.

Clone "am728_60"

A polynucleotide of the present invention has been identified as clone "am728_60". am728_60 was isolated from a human fetal kidney (293 cell line) cDNA library using

methods which are selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. am728_60 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "am728_60 protein").

The nucleotide sequence of am728_60 as presently determined is reported in SEQ ID NO.1. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the am728_60 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO.2.

The EcoRI/NotI restriction fragment obtainable from the deposit containing clone am728_60 should be approximately 4333 bp.

The nucleotide sequence disclosed herein for am728_60 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. am728_60 demonstrated at least some similarity with sequences identified as A4446039 (zw66a08.r1 Soares testis NHT Homo sapiens cDNA clone 781142 5) and U73682 (Human meningioma-expressed antigen 11 (MEA11) mRNA, partial cds). The predicted amino acid sequence disclosed herein for am728_60 was searched against the GenePept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted am728_60 protein demonstrated at least some similarity to sequences identified as U67894 (melanoma inhibitory activity/conductocyte-derived retinoic acid sensitive protein homolog [Rattus norvegicus]), U73682 (meningioma-expressed antigen 11 [Homo sapiens]), U394780 (MEA6 [Homo sapiens]), and X84707 (melanoma growth regulatory protein [Homo sapiens]). Based upon sequence similarity, am728_60 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts three potential transmembrane domains within the am728_60 protein sequence, centered around amino acids 300, 370, and 670 of SEQ ID NO.2, respectively.

When expressed in COS cells, am728_60 protein was detected in a membrane fraction from these cells as a band migrating at approximately 200 kD on a denaturing SDS polyacrylamide gel.

Clone "b377_1"

A polynucleotide of the present invention has been identified as clone "b377_1". b377_1 was isolated from a human fetal brain cDNA library using methods which are

WO 99/32614	PCT/US98/27140	PCT/US98/27140
selective for cDNAs encoding secreted proteins (see U.S. Pat. No. 5,536,637), or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. b377_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "b377_1 protein").	<p>The nucleotide sequence of b377_1 as presently determined is reported in SEQ ID NO:3, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the b377_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:4. Amino acids 27 to 39 of SEQ ID NO:4 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 40. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the b377_1 protein.</p>	<p>The nucleotide sequence of cw354_1 as presently determined is reported in SEQ ID NO:5, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the cw354_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:6. Amino acids 28 to 40 of SEQ ID NO:6 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 41. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the cw354_1 protein.</p>
5	<p>10 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone b377_1 should be approximately 450 bp.</p> <p>The nucleotide sequence disclosed herein for b377_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. b377_1 demonstrated at least some similarity with sequences identified as AA559859 (n148c05.s1 NCL CGAP_P4 Homo sapiens cDNA clone IMAGE1043912), AA657838 (nu08b11.s1 NCL CGAP_P2 Homo sapiens cDNA clone IMAGE1207389 similar to gb:M15990 PROTO-ONCOGENE TYROSINE-PROTEIN KINASE YES (HUMAN)), and R49353 (yg67e07.s1 Homo sapiens cDNA clone 38126 3' similar to contains MER22 repetitive element). Based upon sequence similarity, b377_1 proteins and each similar protein or peptide may share at least some activity.</p>	<p>10 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone cw354_1 should be approximately 1350 bp.</p> <p>The nucleotide sequence disclosed herein for cw354_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. cw354_1 demonstrated at least some similarity with sequences identified as D58859 (Human placenta cDNA 5'-end GEN-514B03), H07863 (y186b05.s1 Homo sapiens cDNA clone 45017 3'), N32178 (yy25b09.s1 Homo sapiens cDNA clone 272249 3'), R81953 (y198e11.r1 Homo sapiens cDNA clone 147308 5'), and W84437 (zd89d06.s1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 356651 3'). The predicted amino acid sequence disclosed herein for cw354_1 was searched against the GenPept and GeneSeq amino acid sequence databases using the BLASTX search protocol. The predicted cw354_1 protein demonstrated at least some similarity to sequences identified as U39726 (adenosinetriphosphatase [Mycoplasma genitalium]). Based upon sequence similarity, cw354_1 proteins and each similar protein or peptide may share at least some activity.</p>
15	<p>20 A polynucleotide of the present invention has been identified as clone "cw354_1".</p> <p>A polynucleotide of the present invention has been identified as clone "cw354_1". A polynucleotide of the present invention has been identified as clone "nm134_4".</p> <p>No. 5,536,637, or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. cw354_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "cw354_1 protein").</p>	<p>20 A polynucleotide of the present invention has been identified as clone "nm134_4".</p> <p>No. 5,536,637, or was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. nm134_4 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "nm134_4 protein").</p>
25		
30		

The nucleotide sequence of nm134_4 as presently determined is reported in SEQ ID NO:7, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the nm134_4 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:8. Amino acids 136 to 148 of SEQ ID NO:8 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 149. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the nm134_4 protein.

10 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone nm134_4 should be approximately 1500 bp.

The nucleotide sequence disclosed herein for nm134_4 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. nm134_4 demonstrated at least some similarity with sequences identified as AA205020 (zq72a12.r1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 647134 5'), AA205286 (zq72a12.s1 Stratagene neuroepithelium (#937231) Homo sapiens cDNA clone 647134 3'), AA261864 (zs18h05.r1 Soares NbHTGBC Homo sapiens cDNA clone 685593 5'), and H63680 (yr55d03.r1 Homo sapiens cDNA clone 209189 5'). Based upon sequence similarity, nm134_4 proteins and each similar protein or peptide may share at least some activity. The TopPredII computer program predicts five potential transmembrane domains within the nm134_4 protein sequence centered around amino acids 108, 132, 170, 195, and 226 of SEQ ID NO:8, respectively.

Clone "yb11_1"

25 A polynucleotide of the present invention has been identified as clone "yb11_1". yb11_1 was isolated from a human fetal brain cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yb11_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "yb11_1 protein").

30 The nucleotide sequence of yb11_1 as presently determined is reported in SEQ ID NO:9, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yb11_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:10. Amino acids 43 to 55 of SEQ ID NO:10 are a predicted leader/signal sequence, with the predicted

mature amino acid sequence beginning at amino acid 56. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yb11_1 protein.

5 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone yb11_1 should be approximately 2800 bp.

The nucleotide sequence disclosed herein for yb11_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yb11_1 demonstrated at least some similarity with sequences identified as R55695 (yg88f12.s1 Homo sapiens cDNA clone 40397 3') and R85100 (yo43b05.s1 Homo sapiens cDNA clone 180657 3'). Based upon sequence similarity, yb11_1 proteins and each similar protein or peptide may share at least some activity.

Clone "yc2_1"

15 A polynucleotide of the present invention has been identified as clone "yc2_1". yc2_1 was isolated from a human fetal kidney (293 cell line) cDNA library and was identified as encoding a secreted or transmembrane protein on the basis of computer analysis of the amino acid sequence of the encoded protein. yc2_1 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "yc2_1 protein").

20 The nucleotide sequence of yc2_1 as presently determined is reported in SEQ ID NO:11, and includes a poly(A) tail. What applicants presently believe to be the proper reading frame and the predicted amino acid sequence of the yc2_1 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:12. Amino acids 15 to 27 of SEQ ID NO:12 are a predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 28. Due to the hydrophobic nature of the predicted leader/signal sequence, it is likely to act as a transmembrane domain should the predicted leader/signal sequence not be separated from the remainder of the yc2_1 protein.

30 The EcoRI/NotI restriction fragment obtainable from the deposit containing clone yc2_1 should be approximately 2900 bp.

The nucleotide sequence disclosed herein for yc2_1 was searched against the GenBank and GeneSeq nucleotide sequence databases using BLASTN/BLASTX and FASTA search protocols. yc2_1 demonstrated at least some similarity with sequences

identified as AA618531 (np38a03.s1 NCL_CGAP_Lu1 Homo sapiens cDNA clone IMAGE:1118572 similar to contains Alu repetitive element) and AA626937 (af84h07.s1 Soares testis NHT Homo sapiens cDNA clone 1048765 3'). Based upon sequence similarity, yc2_1 proteins and each similar protein or peptide may share at least some activity. The nucleotide sequence of yc2_1 indicates that it may contain one or more Alu repetitive elements.

5

Deposit of Clones

Clones am728_60, b377_1, cw354_1, nm134_4, yb11_1, and yc2_1 were deposited on December 19, 1997 with the American Type Culture Collection (10801 University Boulevard, Manassas, Virginia 20110-2209 U.S.A.) as an original deposit under the Budapest Treaty and were given the accession number ATCC 98621, from which each clone comprising a particular polynucleotide is obtainable. All restrictions on the availability to the public of the deposited material will be irrevocably removed upon the granting of the patent, except for the requirements specified in 37 C.F.R. § 1.808(b), and the term of the deposit will comply with 37 C.F.R. § 1.806.

15

Each clone has been transfected into separate bacterial cells (*E. coli*) in this composite deposit. Each clone can be removed from the vector in which it was deposited by performing an EcoRI/NotI digestion (5' site, EcoRI; 3' site, NotI) to produce the appropriate fragment for such clone. Each clone was deposited in either the pED6 or pNOTs vector depicted in Figures 1A and 1B, respectively. The pED6dpc2 vector ("pED6") was derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning (Kaufman *et al.*, 1991, *Nucleic Acids Res.* 19: 4485-4490); the pNOTs vector was derived from pMT2 (Kaufman *et al.*, 1989, *Mol. Cell. Biol.* 9: 946-958) by deletion of the DHFR sequences, insertion of a new polylinker, and insertion of the M13 origin of replication in the ClaI site. In some instances, the deposited clone can become "flipped" (i.e., in the reverse orientation) in the deposited isolate. In such instances, the cDNA insert can still be isolated by digestion with EcoRI and NotI. However, NotI will then produce the 5' site and EcoRI will produce the 3' site for placement of the cDNA in proper orientation for expression in a suitable vector. The cDNA may also be expressed from the vectors in which they were deposited.

30

Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

27

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of an oligonucleotide probe that was used to isolate or to sequence each full-length clone is identified below, and should be most reliable in isolating the clone of interest.

5

<u>Clone</u>	<u>Probe Sequence</u>
am728_60	SEQ ID NO:13
cw354_1	SEQ ID NO:14
nm134_4	SEQ ID NO:15
yb11_1	SEQ ID NO:16
yc2_1	SEQ ID NO:17

10

In the sequences listed above which include an N at position 2, that position is occupied in preferred probes/primers by a biotinylated phosphoramidite residue rather than a nucleotide (such as, for example, that produced by use of biotin phosphoramidite (1-dimethoxytrityloxy-2-(N-biotinyl-4-aminobutyl)-propyl-3-O-(2-cyanoethyl)-(N,N-diisopropyl)-phosphoramidite) (Glen Research, cat. no. 10-1953)).

15

The design of the oligonucleotide probe should preferably follow these parameters:

20

- (a) It should be designed to an area of the sequence which has the fewest ambiguous bases ("N's"), if any;
- (b) It should be designed to have a T_m of approx. 80 ° C (assuming 2° for each A or T and 4 degrees for each G or C).

(b)

The oligonucleotide should preferably be labeled with γ -³²P ATP (specific activity 6000 Ci/mmol) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Other labeling techniques can also be used. Unincorporated label should preferably be removed by gel filtration chromatography or other established methods. The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter. Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmol.

30

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 μ l of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 100 μ g/ml. The culture should preferably be

28

grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth. Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 100 µg/ml and agar at 1.5% in a 150 mm petri dish when grown overnight at 37°C. Other known methods of obtaining distinct, well-separated colonies can also be employed.

Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them.

The filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175.3 g NaCl/liter, 88.2 g Na citrate/liter, adjusted to pH 7.0 with NaOH) containing 0.5% SDS, 100 µg/ml of yeast RNA, and 10 mM EDTA (approximately 10 mL per 150 mm filter). Preferably, the probe is then added to the hybridization mix at a concentration greater than or equal to 1e+6 dpm/mL. The filter is then preferably incubated at 65°C with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2X SSC/0.5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0.1% SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0.1X SSC/0.5% SDS at 65°C for 30 minutes to 1 hour is optional. The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film. Other known hybridization methods can also be employed.

The positive colonies are picked, grown in culture, and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysis, hybridization analysis, or DNA sequencing.

Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, *et al.*, *Bio/Technology* 10: 773-778 (1992) and in R.S. McDowell, *et al.*, *J. Amer. Chem. Soc.* 114: 9245-9253 (1992), both of which are incorporated herein by reference. Such fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites. For example, fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin. For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule. Other immunoglobulin isotypes may also

WO 99/32614 PCT/US98/27140

be used to generate such fusions. For example, a protein - IgM fusion would generate a decavalent form of the protein of the invention.

The present invention also provides both full-length and mature forms of the disclosed proteins. The full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone. The mature form(s) of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell. The sequence(s) of the mature form(s) of the protein may also be determinable from the amino acid sequence of the full-length form.

The present invention also provides genes corresponding to the polynucleotide sequences disclosed herein. "Corresponding genes" are the regions of the genome that are transcribed to produce the mRNAs from which cDNA polynucleotide sequences are derived and may include contiguous regions of the genome necessary for the regulated expression of such genes. Corresponding genes may therefore include but are not limited to coding sequences, 5' and 3' untranslated regions, alternatively spliced exons, introns, promoters, enhancers, and silencer or suppressor elements. The corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials. An "isolated gene" is a gene that has been separated from the adjacent coding sequences, if any, present in the genome of the organism from which the gene was isolated.

The chromosomal location corresponding to the polynucleotide sequences disclosed herein may also be determined, for example by hybridizing appropriately labeled polynucleotides of the present invention to chromosomes *in situ*. It may also be possible to determine the corresponding chromosomal location for a disclosed polynucleotide by identifying significantly similar nucleotide sequences in public databases, such as expressed sequence tags (ESTs), that have already been mapped to particular chromosomal locations. For at least some of the polynucleotide sequences disclosed herein, public database sequences having at least some similarity to the polynucleotide of the present invention have been listed by database accession number. Searches using the GenBank accession numbers of these public database sequences can then be performed at an Internet site provided by the National Center for Biotechnology Information having the address <http://www.ncbi.nlm.nih.gov/UniGene/>, in order to

identify "UniGene clusters" of overlapping sequences. Many of the "UniGene clusters" so identified will already have been mapped to particular chromosomal sites.

Organisms that have enhanced, reduced, or modified expression of the gene(s) corresponding to the polynucleotide sequences disclosed herein are provided. The desired change in gene expression can be achieved through the use of antisense polynucleotides or ribozymes that bind and/or cleave the mRNA transcribed from the gene (Albert and Morris, 1994, *Trends Pharmacol. Sci.* 15(7): 250-254; Lavarosky *et al.*, 1997, *Biochem. Mol. Med.* 62(1): 11-22; and Hampel, 1998, *Prog. Nucleic Acid Res. Mol. Biol.* 58: 1-39; all of which are incorporated by reference herein). Transgenic animals that have multiple copies of the gene(s) corresponding to the polynucleotide sequences disclosed herein, preferably produced by transformation of cells with genetic constructs that are stably maintained within the transformed cells and their progeny, are provided. Transgenic animals that have modified genetic control regions that increase or reduce gene expression levels, or that change temporal or spatial patterns of gene expression, are also provided (see European Patent No. 0 649 464 B1, incorporated by reference herein). In addition, organisms are provided in which the gene(s) corresponding to the polynucleotide sequences disclosed herein have been partially or completely inactivated, through insertion of extraneous sequences into the corresponding gene(s) or through deletion of all or part of the corresponding gene(s). Partial or complete gene inactivation can be accomplished through insertion, preferably followed by imprecise excision, of transposable elements (Plasterk, 1992, *Bioessays* 14(9): 629-633; Zwaal *et al.*, 1993, *Proc. Natl. Acad. Sci. USA* 90(16): 7431-7435; Clark *et al.*, 1994, *Proc. Natl. Acad. Sci. USA* 91(2): 719-722; all of which are incorporated by reference herein), or through homologous recombination, preferably detected by positive/negative genetic selection strategies (Mansour *et al.*, 1988, *Nature* 336: 348-352; U.S. Patent Nos. 5,464,764; 5,487,992; 5,627,059; 5,631,153; 5,614,396; 5,616,491; and 5,679,523; all of which are incorporated by reference herein). These organisms with altered gene expression are preferably eukaryotes and more preferably are mammals. Such organisms are useful for the development of non-human models for the study of disorders involving the corresponding gene(s), and for the development of assay systems for the identification of molecules that interact with the protein product(s) of the corresponding gene(s).

Where the protein of the present invention is membrane-bound (e.g., is a receptor), the present invention also provides for soluble forms of such protein. In such forms, part or all of the intracellular and transmembrane domains of the protein are deleted such that

the protein is fully secreted from the cell in which it is expressed. The intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information. For example, the TopPredII computer program can be used to predict the location of transmembrane domains in an amino acid sequence, domains which are described by the location of the center of the transmembrane domain, with at least ten transmembrane amino acids on each side of the reported central residue(s).

Proteins and protein fragments of the present invention include proteins with amino acid sequence lengths that are at least 25% (more preferably at least 50%, and most preferably at least 75%) of the length of a disclosed protein and have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with that disclosed protein, where sequence identity is determined by comparing the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Also included in the present invention are proteins and protein fragments that contain a segment preferably comprising 8 or more (more preferably 20 or more, most preferably 30 or more) contiguous amino acids that shares at least 75% sequence identity (more preferably, at least 85% identity; most preferably at least 95% identity) with any such segment of any of the disclosed proteins.

In particular, sequence identity may be determined using WU-BLAST (Washington University BLAST) version 2.0 software, which builds upon WU-BLAST version 1.4, which in turn is based on the public domain NCBI-BLAST version 1.4 (Altschul and Gish, 1996, Local alignment statistics, Doolittle *ed.*, *Methods in Enzymology* 266: 460-480; Altschul *et al.*, 1990, Basic local alignment search tool, *Journal of Molecular Biology* 215: 403-410; Gish and States, 1993, Identification of protein coding regions by database similarity search, *Nature Genetics* 3: 266-272; Karlin and Altschul, 1993, Applications and statistics for multiple high-scoring segments in molecular sequences, *Proc. Natl. Acad. Sci. USA* 90: 5873-5877; all of which are incorporated by reference herein). WU-BLAST version 2.0 executable programs for several UNIX platforms can be downloaded from [ftp://blast.wustl.edu/blast/executables](http://blast.wustl.edu/blast/executables). The complete suite of search programs (BLASTP, BLASTN, BLASTX, TBLASTX, and TBLASTN) is provided at that site, in addition to several support programs. WU-BLAST 2.0 is copyrighted and may not be sold or redistributed in any form or manner without the express written consent of the author; but the posted executables may otherwise be freely

used for commercial, nonprofit, or academic purposes. In all search programs in the suite -- BLASTP, BLASTN, BLASTX, TBLASTN and TBLASTX -- the gapped alignment routines are integral to the database search itself, and thus yield much better sensitivity and selectivity while producing the more easily interpreted output. Gapping can optionally be turned off in all of these programs, if desired. The default penalty (Q) for a gap of length one is Q=9 for proteins and BLASTP, and Q=10 for BLASTN, but may be changed to any integer value including zero, one through eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. The default per-residue penalty for extending a gap (R) is R=2 for proteins and BLASTP, and R=10 for BLASTN, but may be changed to any integer value including zero, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve through twenty, twenty-one through fifty, fifty-one through one hundred, etc. Any combination of values for Q and R can be used in order to align sequences so as to maximize overlap and identity while minimizing sequence gaps. The default amino acid comparison matrix is BLOSUM62, but other amino acid comparison matrices such as PAM can be utilized.

Species homologues of the disclosed polynucleotides and proteins are also provided by the present invention. As used herein, a "species homologue" is a protein or polynucleotide with a different species of origin from that of a given protein or polynucleotide, but with significant sequence similarity to the given protein or polynucleotide. Preferably, polynucleotide species homologues have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, and protein species homologues have at least 30% sequence identity (more preferably, at least 45% identity; most preferably at least 60% identity) with the given protein, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides or the amino acid sequences of the proteins when aligned so as to maximize overlap and identity while minimizing sequence gaps. Species homologues may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species. Preferably, species homologues are those isolated from mammalian species. Most preferably, species homologues are those isolated from certain mammalian species such as, for example, *Pan troglodytes*, *Gorilla gorilla*, *Pongo pygmaeus*, *Hylobates concolor*, *Macaca mulatta*, *Papio papio*, *Papio hamadryas*, *Cercopithecus aethiops*, *Cebus capucinus*,

Aotus tringoides, *Sanguinus oedipus*, *Microcebus murinus*, *Mus musculus*, *Rattus norvegicus*, *Cricetus griseus*, *Felis catus*, *Mustela vison*, *Canis familiaris*, *Oryctolagus cuniculus*, *Bos taurus*, *Ovis aries*, *Sus scrofa*, and *Equus caballus*, for which genetic maps have been created allowing the identification of syntenic relationships between the genomic organization of genes in one species and the genomic organization of the related genes in another species (O'Brien and Seuanez, 1988, *Ann. Rev. Genet.* 22: 323-351; O'Brien *et al.*, 1993, *Nature Genetics* 3:103-112; Johansson *et al.*, 1995, *Genomics* 25: 682-690; Lyons *et al.*, 1997, *Nature Genetics* 15: 47-56; O'Brien *et al.*, 1997, *Trends in Genetics* 13(10): 393-399; Carver and Stubbs, 1997, *Genome Research* 7:1123-1137, all of which are incorporated by reference herein).

The invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative forms of the isolated polynucleotides which also encode proteins which are identical or have significantly similar sequences to those encoded by the disclosed polynucleotides. Preferably, allelic variants have at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% identity) with the given polynucleotide, where sequence identity is determined by comparing the nucleotide sequences of the polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps. Allelic variants may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from individuals of the appropriate species.

The invention also includes polynucleotides with sequences complementary to those of the polynucleotides disclosed herein.

The present invention also includes polynucleotides that hybridize under reduced stringency conditions, more preferably stringent conditions, and most preferably highly stringent conditions, to polynucleotides described herein. Examples of stringency conditions are shown in the table below: highly stringent conditions are those that are at least as stringent as, for example, conditions A-F; stringent conditions are at least as stringent as, for example, conditions G-I; and reduced stringency conditions are at least as stringent as, for example, conditions M-R.

Stringency Condition	Polynucleotide Hybrid	Hybrid Length (bp) [†]	Hybridization Temperature and Buffer [†]	Wash Temperature and Buffer [†]
A	DNA:DNA	≥ 50	65°C; 1xSSC -or- 42°C; 1xSSC, 50% formamide	65°C; 0.3xSSC
B	DNA:DNA	<50	T _H [†] ; 1xSSC	T _H [†] ; 1xSSC
C	DNA:RNA	≥ 50	67°C; 1xSSC -or- 45°C; 1xSSC, 50% formamide	67°C; 0.3xSSC
D	DNA:RNA	<50	T _D [†] ; 1xSSC	T _D [†] ; 1xSSC
E	RNA:RNA	≥ 50	70°C; 1xSSC -or- 50°C; 1xSSC, 50% formamide	70°C; 0.3xSSC
F	RNA:RNA	<50	T _F [†] ; 1xSSC	T _F [†] ; 1xSSC
G	DNA:DNA	≥ 50	65°C; 4xSSC -or- 42°C; 4xSSC, 50% formamide	65°C; 1xSSC
H	DNA:DNA	<50	T _H [†] ; 4xSSC	T _H [†] ; 4xSSC
I	DNA:RNA	≥ 50	67°C; 4xSSC -or- 45°C; 4xSSC, 50% formamide	67°C; 1xSSC
J	DNA:RNA	<50	T _J [†] ; 4xSSC	T _J [†] ; 4xSSC
K	RNA:RNA	≥ 50	70°C; 4xSSC -or- 50°C; 4xSSC, 50% formamide	67°C; 1xSSC
L	RNA:RNA	<50	T _L [†] ; 2xSSC	T _L [†] ; 2xSSC
M	DNA:DNA	≥ 50	50°C; 4xSSC -or- 40°C; 6xSSC, 50% formamide	50°C; 2xSSC
N	DNA:DNA	<50	T _N [†] ; 6xSSC	T _N [†] ; 6xSSC
O	DNA:RNA	≥ 50	55°C; 4xSSC -or- 42°C; 6xSSC, 50% formamide	55°C; 2xSSC
P	DNA:RNA	<50	T _P [†] ; 6xSSC	T _P [†] ; 6xSSC
Q	RNA:RNA	≥ 50	60°C; 4xSSC -or- 45°C; 6xSSC, 50% formamide	60°C; 2xSSC
R	RNA:RNA	<50	T _R [†] ; 4xSSC	T _R [†] ; 4xSSC

[†] The hybrid length is that anticipated for the hybridized region(s) of the hybridizing polynucleotides. When hybridizing a polynucleotide to a target polynucleotide of unknown sequence, the hybrid length is assumed to be that of the hybridizing polynucleotide. When polynucleotides of known sequence are hybridized, the hybrid length can be determined by aligning the sequences of the polynucleotides and identifying the region or regions of optimal sequence complementarity.

[†] T_H - T_R: The hybridization temperature for hybrids anticipated to be less than 50 base pairs in length should be 5-10°C less than the melting temperature (T_m) of the hybrid, where T_m is determined according to the following equations. For hybrids less than 18 base pairs in length, T_m(°C) = 2(# of A + T bases) + 4(# of G + C bases). For hybrids between 18 and 49 base pairs in length, T_m(°C) = 81.5 + 16.6(log₁₀[Na⁺]) + 0.41(%G+C) - (600/N), where N is the number of bases in the hybrid, and [Na⁺] is the concentration of sodium ions in the hybridization buffer [Na⁺] for 1xSSC = 0.165 M).

[†] SSPE (1xSSPE is 0.15M NaCl, 10mM NaH₂PO₄, and 1.25mM EDTA, pH 7.4) can be substituted for SSC (1xSSC is 0.15M NaCl and 15mM sodium citrate) in the hybridization and wash buffers; washes are performed for 15 minutes after hybridization is complete.

Additional examples of stringency conditions for polynucleotide hybridization are provided in Sambrook, J., E.F. Fritsch, and T. Maniatis, 1989, *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, chapters 9 and 11, and *Current Protocols in Molecular Biology*, 1995, F.M. Ausubel et al., eds., John Wiley & Sons, Inc., sections 2.10 and 6.3-6.4, incorporated herein by reference.

Preferably, each such hybridizing polynucleotide has a length that is at least 25%(more preferably at least 50%, and most preferably at least 75%) of the length of the polynucleotide of the present invention to which it hybridizes, and has at least 60% sequence identity (more preferably, at least 75% identity; most preferably at least 90% or 95% identity) with the polynucleotide of the present invention to which it hybridizes, where sequence identity is determined by comparing the sequences of the hybridizing polynucleotides when aligned so as to maximize overlap and identity while minimizing sequence gaps.

The isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman *et al.*, *Nucleic Acids Res.* 19, 4485-4490 (1991), in order to produce the protein recombinantly. Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, *Methods in Enzymology* 185, 537-566 (1990). As defined herein "operably linked" means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.

A number of types of cells may act as suitable host cells for expression of the protein. Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from *in vitro* culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL-60, U937, HaK or Jurkat cells.

Alternatively, it may be possible to produce the protein in lower eukaryotes such as yeast or in prokaryotes such as bacteria. Potentially suitable yeast strains include *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Kluyveromyces* strains, *Candida*, or any yeast strain capable of expressing heterologous proteins. Potentially suitable bacterial strains include *Escherichia coli*, *Bacillus subtilis*, *Salmonella typhimurium*, or any bacterial

strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.

The protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system. Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, *Texas Agricultural Experiment Station Bulletin No. 1555 (1982)*, incorporated herein by reference. As used herein, an insect cell capable of expressing a polynucleotide of the present invention is "transformed."

The protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein. The resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography. The purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A-agarose, heparin-tyoppear® or Cibacron blue 3GA Sepharose®, one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether, or immunoaffinity chromatography.

Alternatively, the protein of the invention may also be expressed in a form which will facilitate purification. For example, it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England Biolabs (Beverly, MA), Pharmacia (Piscataway, NJ) and Invitrogen Corporation (Carlsbad, CA), respectively. The protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope. One such epitope ("Flag") is commercially available from the Eastman Kodak Company (New Haven, CT).

Finally, one or more reverse-phase high performance liquid chromatography (RP-HPLC) steps employing hydrophobic RP-HPLC media, e.g., silica gel having pendant methyl or other aliphatic groups, can be employed to further purify the protein. Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein. The protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein."

The protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.

The protein may also be produced by known conventional chemical synthesis. Methods for constructing the proteins of the present invention by synthetic means are known to those skilled in the art. The synthetically-constructed protein sequences, by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies.

The proteins provided herein also include proteins characterized by amino acid sequences similar to those of purified proteins but into which modification are naturally provided or deliberately engineered. For example, modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques. Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence. For example, one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule. Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e.g., U.S. Patent No. 4,518,584). Preferably, such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein.

Other fragments and derivatives of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art

given the disclosures herein. Such modifications are believed to be encompassed by the present invention.

5 USES AND BIOLOGICAL ACTIVITY

The polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below. Uses or activities described for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA).

Research Uses and Utilities

The polynucleotides provided by the present invention can be used by the research community for various purposes. The polynucleotides can be used to express recombinant protein for analysis, characterization or therapeutic use; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states); as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip" or other support, including for examination of expression patterns; to raise anti-protein antibodies using DNA immunization techniques; and as an antigen to raise anti-DNA antibodies or elicit another immune response. Where the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the polynucleotide can also be used in interaction trap assays (such as, for example, those described in Gyuris *et al.*, 1993, *Cell* 75: 791-803 and in Rossi *et al.*, 1997, *Proc. Natl. Acad. Sci. USA* 94: 8405-8410, all of which are incorporated by reference herein) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.

The proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands. Where the protein binds or potentially binds to another protein (such as, for example, in a receptor-ligand interaction), the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction.

Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.

Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include without limitation "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E.F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S.L. and A.R. Kimmel eds., 1987.

Nutritional Uses

Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate. In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules. In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured.

Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may

induce production of other cytokines in certain cell populations. Many protein factors discovered to date, including all known cytokines, have exhibited activity in one or more factor-dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/11, BaF3, MC9/G, M+ (preB M+) 2E8, RB5, DA1, 123, T1165, HT2, CTLL2, TF-1, Mo7e and CMK.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Krusbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1.3-19; Chapter 7, Immunologic studies in Humans); Takai et al., *J. Immunol.* 137:3494-3500, 1986; Bertagnoli et al., *J. Immunol.* 145:1706-1712, 1990; Bertagnoli et al., *Cellular Immunology*, 133:327-341, 1991; Bertagnoli, et al., *J. Immunol.* 149:3778-3783, 1992; Bowman et al., *J. Immunol.* 152: 1756-1761, 1994.

Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those described in: *Polyclonal T cell stimulation*, Krusbeek, A.M. and Shevach, E.M. In *Current Protocols in Immunology*, J.E.a. Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto, 1994; and *Measurement of mouse and human Interferon γ* , Schreiber, R.D. In *Current Protocols in Immunology*, J.E.a. Coligan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto, 1994.

Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: *Measurement of Human and Murine Interleukin 2 and Interleukin 4*, Bottomly, K., Davis, L.S. and Lipsky, P.E. In *Current Protocols in Immunology*, J.E.a. Coligan eds. Vol 1 pp. 6.3.1-6.3.12, John Wiley and Sons, Toronto, 1991; deVries et al., *J. Exp. Med.* 173:1205-1211, 1991; Moreau et al., *Nature* 336:690-692, 1988; Greenberger et al., *Proc. Natl. Acad. Sci. U.S.A.* 80:2931-2938, 1983; *Measurement of mouse and human interleukin 6* - Nordan, R. In *Current Protocols in Immunology*, J.E.a. Coligan eds. Vol 1 pp. 6.6.1-6.6.5, John Wiley and Sons, Toronto, 1991; Smith et al., *Proc. Natl. Acad. Sci. U.S.A.* 83:1857-1861, 1986; *Measurement of human Interleukin 11* - Bennett, F., Giannotti, J., Clark, S.C. and Turner, K. J. In *Current Protocols*

in *Immunology*, J.E.a. Coligan eds. Vol 1 pp. 6.15.1 John Wiley and Sons, Toronto, 1991; *Measurement of mouse and human Interleukin 9* - Ciarletta, A., Giannotti, J., Clark, S.C. and Turner, K.J. In *Current Protocols in Immunology*, J.E.a. Coligan eds. Vol 1 pp. 6.13.1, John Wiley and Sons, Toronto, 1991.

Assays for T-cell clone responses to antigens (which will identify, among others, proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J. E. Coligan, A.M. Krusbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function; Chapter 6, Cytokines and their cellular receptors; Chapter 7, Immunologic studies in Humans); Weinberger et al., *Proc. Natl. Acad. Sci. USA* 77:6091-6095, 1980; Weinberger et al., *Eur. J. Immun.* 11:405-411, 1981; Takai et al., *J. Immunol.* 137:3494-3500, 1986; Takai et al., *J. Immunol.* 140:508-512, 1988.

Immune Stimulating or Suppressing Activity

A protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein. A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as affecting the cytolytic activity of NK cells and other cell populations. These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders. More specifically, infectious diseases caused by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, *Leishmania* spp., malaria spp. and various fungal infections such as candidiasis. Of course, in this regard, a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i.e., in the treatment of cancer.

Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis,

myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease. Such a protein of the present invention may also be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems. Other conditions, in which immune suppression is desired (including, for example, organ transplantation), may also be treatable using a protein of the present invention.

Using the proteins of the invention it may also be possible to regulate immune responses in a number of ways. Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response. The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both. Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent. Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased. Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent.

Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such as, for example, B7)), *e.g.*, preventing high level lymphokine synthesis by activated T cells, will be useful in situations of tissue, skin and organ transplantation and in graft-versus-host disease (GVHD). For example, blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typically, in tissue transplants, rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a soluble, monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (*e.g.*, B7-1, B7-3) or blocking antibody), prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal. Blocking B lymphocyte antigen function in this manner prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant. Moreover, the lack of costimulation may also be sufficient to

anergize the T cells, thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents. To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens.

The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans. Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins *in vivo* as described in Lenschow *et al.*, Science 257:789-792 (1992) and Turka *et al.*, Proc. Natl. Acad. Sci USA, 89:11102-11105 (1992). In addition, murine models of GVHD (see Paul *et al.*, Fundamental Immunology, Raven Press, New York, 1989, pp. 846-847) can be used to determine the effect of blocking B lymphocyte antigen function *in vivo* on the development of that disease.

Blocking antigen function may also be therapeutically useful for treating autoimmune diseases. Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases. Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms. Administration of reagents which block costimulation of T cells by disrupting receptor:ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process. Additionally, blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease. The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases. Examples include murine experimental autoimmune encephalitis, systemic lupus erythematosus in MRL/lpr/lpr mice or NZB hybrid mice, murine autoimmune collagen arthritis, diabetes mellitus in NOD mice and BB rats, and murine experimental myasthenia gravis (see Paul *et al.*, Fundamental Immunology, Raven Press, New York, 1989, pp. 840-856).

Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy.

Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection. In addition, systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically.

Alternatively, anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimulating the T cells *in vitro* with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the *in vitro* activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient. The infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells *in vivo*.

In another application, up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject. If desired, the tumor cell can be transfected to express a combination of peptides. For example, tumor cells obtained from a patient can be transfected *ex vivo* with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-1-like activity and/or B7-3-like activity. The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell. Alternatively, gene therapy techniques can be used to target a tumor cell for transfection *in vivo*.

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells. In addition, tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a

cytoplasmic-domain truncated portion) of an MHC class I α chain protein and β_2 microglobulin protein or an MHC class II α chain protein and an MHC class II β chain protein to thereby express MHC class I or MHC class II proteins on the cell surface. Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e.g., B7-1, B7-2, B7-3) induces a T cell mediated immune response against the transfected tumor cell. Optionally, a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the invariant chain, can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity. Thus, the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Krusbeek, D.H. Margulies, E.M. Shevach, W. Stöber, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Hermann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Hermann et al., J. Immunol. 128:1966-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Hermann et al., Proc. Natl. Acad. Sci. USA 78:2488-2492, 1981; Hermann et al., J. Immunol. 128:1966-1974, 1982; Handa et al., J. Immunol. 135:1564-1572, 1985; Takai et al., J. Immunol. 137:3494-3500, 1986; Bowman et al., J. Virology 61:1992-1998; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnoli et al., Cellular Immunology 133:327-341, 1991; Brown et al., J. Immunol. 153:3079-3092, 1994.

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify, among others, proteins that modulate T-cell dependent antibody responses and that affect Th1/Th2 profiles) include, without limitation, those described in: Maliszewski, J. Immunol. 144:3028-3033, 1990; and Assays for B cell function: *In vitro* antibody production, Mond, J.J. and Brunschwic, M. In *Current Protocols in Immunology*, J.E.a. Coligan eds. Vol 1 pp. 3.8.1-3.8.16, John Wiley and Sons, Toronto. 1994.

Mixed lymphocyte reaction (MLR) assays (which will identify, among others, proteins that generate predominantly Th1 and CTL responses) include, without limitation,

those described in: Current Protocols in Immunology, Ed by J. E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3; In Vitro assays for Mouse Lymphocyte Function 3.1-3.19; Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol. 137:3494-3500, 1986; Takai et al., J. Immunol. 140:508-512, 1988; Bertagnoli et al., J. Immunol. 149:3778-3783, 1992.

Dendritic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in: Guéry et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Experimental Medicine 173:549-559, 1991; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961-965, 1994; Macatonia et al., Journal of Experimental Medicine 169:1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inaba et al., Journal of Experimental Medicine 172:631-640, 1990.

Assays for lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53:1945-1951, 1993; Itoh et al., Cell 66:233-243, 1991; Zacharchuk, Journal of Immunology 145:4037-4045, 1990; Zamai et al., Cytometry 14:891-897, 1993; Gorczyca et al., International Journal of Oncology 1:639-648, 1992.

Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al., Blood 84:111-117, 1994; Fine et al., Cellular Immunology 155:111-122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad. Sci. USA 88:7548-7551, 1991.

Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g. in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid

precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complementary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above-mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantation, including, without limitation, aplastic anemia and paroxysmal nocturnal hemoglobinuria), as well as in repopulating the stem cell compartment post irradiation/chemotherapy, either *in-vivo* or *ex-vivo* (i.e., in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above.

Assays for embryonic stem cell differentiation (which will identify, among others, proteins that influence embryonic differentiation hematopoiesis) include, without limitation, those described in: Johansson et al. Cellular Biology 15:141-151, 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81:2903-2915, 1993.

Assays for stem cell survival and differentiation (which will identify, among others, proteins that regulate lympho-hematopoiesis) include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol. pp. 265-268, Wiley-Liss, Inc., New York, NY, 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol. pp. 23-39, Wiley-Liss, Inc., New York, NY, 1994; Neben et al., Experimental Hematology 22:353-359, 1994; Cobblestone area forming cell assay, Ploemacher, R.E. In *Culture of Hematopoietic Cells*. R.I. Freshney, et al. eds. Vol. pp. 1-21, Wiley-Liss, Inc., New York, NY, 1994; Long

term bone marrow cultures in the presence of stromal cells, Spooncer, E., Dexter, M. and Allen, T. In *Culture of Hematopoietic Cells*. R.I. Freshney, *et al.* eds. Vol pp. 163-179, Wiley-Liss, Inc., New York, NY, 1994; Long term culture initiating cell assay, Sutherland, H.J. In *Culture of Hematopoietic Cells*, R.I. Freshney, *et al.* eds. Vol pp. 139-162, Wiley-Liss, Inc., New York, NY, 1994.

Tissue Growth Activity

A protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.

A protein of the present invention, which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals. Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. *De novo* bone formation induced by an osteogenic agent contributes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery.

A protein of this invention may also be used in the treatment of periodontal disease, and in other tooth repair processes. Such agents may provide an environment to attract bone-forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells. A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity, osteoclast activity, etc.) mediated by inflammatory processes.

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation. A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as

well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. *De novo* tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells, induce differentiation of progenitors of tendon- or ligament-forming cells, or induce growth of tendon/ligament cells or progenitors *ex vivo* for return *in vivo* to effect tissue repair. The compositions of the invention may also be useful in the treatment of tendinitis, carpal tunnel syndrome and other tendon or ligament defects. The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art.

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, *i.e.* for the treatment of central and peripheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue. More specifically, a protein may be used in the treatment of diseases of the peripheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.

Proteins of the invention may also be useful to promote better or faster closure of non-healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.

It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues. Part of the desired effects may be by inhibition or modulation

of fibrotic scarring to allow normal tissue to regenerate. A protein of the invention may also exhibit angiogenic activity.

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium).

Assays for wound healing activity include, without limitation, those described in: Winter, *Epidermal Wound Healing*, pps. 71-112 (Maibach, HI and Rovee, DT, eds.), Year Book Medical Publishers, Inc., Chicago, as modified by Eaglestein and Mertz, J. Invest. Dermatol 71:382-84 (1978).

20 Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin α family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively, the protein of the invention, as a homodimer or as a heterodimer with other protein subunits of the inhibin β group, may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885. A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for activin/inhibin activity include, without limitation, those described in: Vale et al., *Endocrinology* 91:562-572, 1972; Ling et al., *Nature* 321:779-782, 1986; Vale et al., *Nature* 321:776-779, 1986; Mason et al., *Nature* 318:659-663, 1985; Forage et al., *Proc. Natl. Acad. Sci. USA* 83:3091-3095, 1986.

Chemotactic/Chemokinetic Activity

A protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells. Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action. Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.

A protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population. Preferably, the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described in: *Current Protocols in Immunology*, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 6.12, Measurement of alpha and beta Chemokines 6.12.1-6.12.28; Taub et al. *J. Clin. Invest.* 95:1370-1376, 1995; Lind et al.

APMIS 103:140-146, 1995; Muller et al Eur. J. Immunol. 25: 1744-1748; Gruber et al. J. of Immunol. 152:5860-5867, 1994; Johnston et al. J. of Immunol. 153: 1762-1768, 1994.

Hemostatic and Thrombolytic Activity

5 A protein of the invention may also exhibit hemostatic or thrombolytic activity.

As a result, such a protein is expected to be useful in treatment of various coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes. A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).

The activity of a protein of the invention may, among other means, be measured by the following methods:

15 Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26:131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibrinolysis 5:71-79 (1991); Schaub, Prostaglandins 35:467-474, 1988.

20 Receptor/Ligand Activity

A protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions. Examples of such receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction. A protein of the present invention (including, without limitation, fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions.

The activity of a protein of the invention may, among other means, be measured by the following methods:

Suitable assays for receptor/ligand activity include without limitation those described in: Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W. Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1-7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med. 168:1145-1156, 1988; Rosenstein et al., J. Exp. Med. 169:149-160, 1989; Stollenberg et al., J. Immunol. Methods 175:59-68, 1994; Stitt et al., Cell 80:661-670, 1995.

10 Anti-Inflammatory Activity

Proteins of the present invention may also exhibit anti-inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response. Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.

25 Cadherin/Tumor Invasion Suppressor Activity

Cadherins are calcium-dependent adhesion molecules that appear to play major roles during development, particularly in defining specific cell types. Loss or alteration of normal cadherin expression can lead to changes in cell adhesion properties linked to tumor growth and metastasis. Cadherin malfunction is also implicated in other human diseases, such as pemphigus vulgaris and pemphigus foliaceus (auto-immune blistering skin diseases), Crohn's disease, and some developmental abnormalities.

The cadherin superfamily includes well over forty members, each with a distinct pattern of expression. All members of the superfamily have in common conserved

extracellular repeats (cadherin domains), but structural differences are found in other parts of the molecule. The cadherin domains bind calcium to form their tertiary structure and thus calcium is required to mediate their adhesion. Only a few amino acids in the first cadherin domain provide the basis for homophilic adhesion; modification of this recognition site can change the specificity of a cadherin so that instead of recognizing only itself, the mutant molecule can now also bind to a different cadherin. In addition, some cadherins engage in heterophilic adhesion with other cadherins.

E-cadherin, one member of the cadherin superfamily, is expressed in epithelial cell types. Pathologically, if E-cadherin expression is lost in a tumor, the malignant cells become invasive and the cancer metastasizes. Transfection of cancer cell lines with polynucleotides expressing E-cadherin has reversed cancer-associated changes by returning altered cell shapes to normal, restoring cells' adhesiveness to each other and to their substrate, decreasing the cell growth rate, and drastically reducing anchorage-independent cell growth. Thus, reintroducing E-cadherin expression reverts carcinomas to a less advanced stage. It is likely that other cadherins have the same invasion suppressor role in carcinomas derived from other tissue types. Therefore, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to treat cancer. Introducing such proteins or polynucleotides into cancer cells can reduce or eliminate the cancerous changes observed in these cells by providing normal cadherin expression.

Cancer cells have also been shown to express cadherins of a different tissue type than their origin, thus allowing these cells to invade and metastasize in a different tissue in the body. Proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be substituted in these cells for the inappropriately expressed cadherins, restoring normal cell adhesive properties and reducing or eliminating the tendency of the cells to metastasize.

Additionally, proteins of the present invention with cadherin activity, and polynucleotides of the present invention encoding such proteins, can be used to generate antibodies recognizing and binding to cadherins. Such antibodies can be used to block the adhesion of inappropriately expressed tumor-cell cadherins, preventing the cells from forming a tumor elsewhere. Such an anti-cadherin antibody can also be used as a marker for the grade, pathological type, and prognosis of a cancer, i.e. the more progressed the cancer, the less cadherin expression there will be, and this decrease in cadherin expression can be detected by the use of a cadherin-binding antibody.

Fragments of proteins of the present invention with cadherin activity, preferably a polypeptide comprising a decapeptide of the cadherin recognition site, and polynucleotides of the present invention encoding such protein fragments, can also be used to block cadherin function by binding to cadherins and preventing them from binding in ways that produce undesirable effects. Additionally, fragments of proteins of the present invention with cadherin activity, preferably truncated soluble cadherin fragments which have been found to be stable in the circulation of cancer patients, and polynucleotides encoding such protein fragments, can be used to disturb proper cell-cell adhesion.

Assays for cadherin adhesive and invasive suppressor activity include, without limitation, those described in: Hortsch et al. J Biol Chem 270 (32): 18809-18817, 1995; Miyaki et al. Oncogene 11: 2547-2552, 1995; Ozawa et al. Cell 63: 1033-1038, 1990.

Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tumors, a protein of the invention may exhibit other anti-tumor activities. A protein may inhibit tumor growth directly or indirectly (such as, for example, via antibody-dependent cell-mediated cytotoxicity (ADCC)). A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth.

Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacteria, viruses, fungi and other parasites; effecting (suppressing or enhancing) bodily characteristics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape); effecting biorhythms or cardiac cycles or rhythms; effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolism, processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional factors or component(s);

5 effecting behavioral characteristics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders) and violent behaviors; providing analgesic effects or other pain reducing effects; promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages; hormonal or endocrine activity; in the case of enzymes, correcting deficiencies of the enzyme and treating deficiency-related diseases; treatment of hyperproliferative disorders (such as, for example, psoriasis); immunoglobulin-like activity (such as, for example, the ability to bind antigens or complement); and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein.

ADMINISTRATION AND DOSING

15 A protein of the present invention (from whatever source derived, including without limitation from recombinant and non-recombinant sources) may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier. Such a composition may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art. The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration. The pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IFN γ , TNF α , TNF β , G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin. The pharmaceutical composition may further contain other agents which either enhance the activity of the protein or complement its activity or use in treatment. Such additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with protein of the invention, or to minimize side effects. Conversely, protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.

5 A protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins. As a result, pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.

10 The pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens. The protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes. B lymphocytes will respond to antigen through their surface immunoglobulin receptor. T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins. MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes. The antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells. Alternatively antibodies able to bind surface immunoglobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.

15 The pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution. Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfaides, lysolactitin, phospholipids, saponin, bile acids, and the like. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No. 4,501,728; U.S. Patent No. 4,837,028; and U.S. Patent No. 4,737,323, all of which are incorporated herein by reference.

20 As used herein, the term "therapeutically effective amount" means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions. When applied to an individual active ingredient, administered alone, the term refers to that ingredient alone. When applied to

a combination, the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, serially or simultaneously.

In practicing the method of treatment or use of the present invention, a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated. Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors. When co-administered with one or more cytokines, lymphokines or other hematopoietic factors, protein of the present invention may be administered either simultaneously with the cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially. If administered sequentially, the attending physician will decide on the appropriate sequence of administering protein of the present invention in combination with cytokine(s), lymphokine(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors.

Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as oral ingestion, inhalation, topical application or cutaneous, subcutaneous, intraperitoneal, parenteral or intravenous injection. Intravenous administration to the patient is preferred.

When a therapeutically effective amount of protein of the present invention is administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir. When administered in tablet form, the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant. The tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention. When administered in liquid form, a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils may be added. The liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol. When administered in liquid form, the pharmaceutical composition contains from about 0.5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention.

When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution.

The preparation of such parenterally acceptable protein solutions, having due regard to pH, isotonicity, stability, and the like, is within the skill in the art. A preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art. The pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.

The amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patient has undergone. Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient. Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response. Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 0.01 µg to about 100 mg (preferably about 0.1mg to about 10 mg, more preferably about 0.1 µg to about 1 mg) of protein of the present invention per kg body weight.

The duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient. It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration. Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.

Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein. Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen. The peptide immunogens additionally may contain a cysteine residue at the

carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH). Methods for synthesizing such peptides are known in the art, for example, as in R.P. Merrifield, *J. Amer. Chem. Soc.* **85**, 2149-2154 (1963); J.L. Kestevenansky, *et al.*, *FEBS Lett.* **211**, 10 (1987). Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein. Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved. In the case of cancerous cells or leukemic cells, neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein.

For compositions of the present invention which are useful for bone, cartilage, tendon or ligament regeneration, the therapeutic method includes administering the composition topically, systemically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention. Preferably for bone and/or cartilage formation, the composition would include a matrix capable of delivering the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body. Such matrices may be formed of materials presently in use for other implanted medical applications.

The choice of matrix material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides. Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen. Further matrices are comprised of pure proteins

or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxyapatite, bioglass, aluminates, or other ceramics. Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate. The bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.

Presently preferred is a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns. In some applications, it will be useful to utilize a sequestering agent, such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.

A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorption of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.

In further compositions, proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question. These agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- α and TGF- β), and insulin-like growth factor (IGF).

The therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention. The dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician considering

various factors which modify the action of the proteins, e.g., amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e.g., bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of matrix used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition. For example, the addition of other known growth factors, such as IGF-I (insulin like growth factor I), to the final composition, may also effect the dosage. Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometric determinations and tetracycline labeling.

Polynucleotides of the present invention can also be used for gene therapy. Such polynucleotides can be introduced either *in vivo* or *ex vivo* into cells for expression in a mammalian subject. Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA).

Cells may also be cultured *ex vivo* in the presence of proteins of the present invention in order to proliferate or to produce a desired effect on or activity in such cells. Treated cells can then be introduced *in vivo* for therapeutic purposes.

Patent and literature references cited herein are incorporated by reference as if fully set forth.

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:
 - (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:1 from nucleotide 179 to nucleotide 4285;
 - (c) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone am728_60 deposited under accession number ATCC 98621;
 - (d) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone am728_60 deposited under accession number ATCC 98621;
 - (e) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:2;
 - (f) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:2;
 - (g) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above; and
 - (h) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(f).
2. The polynucleotide of claim 1 wherein said polynucleotide is operably linked to at least one expression control sequence.
3. A host cell transformed with the polynucleotide of claim 2.
4. The host cell of claim 3, wherein said cell is a mammalian cell.
5. A process for producing a protein encoded by the polynucleotide of claim 2, which process comprises:
 - (a) growing a culture of the host cell of claim 3 in a suitable culture medium; and
 - (b) purifying said protein from the culture.
6. A protein produced according to the process of claim 5.

7. An isolated polynucleotide encoding the protein of claim 6.

8. The polynucleotide of claim 7, wherein the polynucleotide comprises the cDNA insert of clone am728_60 deposited under accession number ATCC 98621.

9. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:2;
 - (b) fragments of the amino acid sequence of SEQ ID NO:2, each fragment comprising eight consecutive amino acids of SEQ ID NO:2; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone am728_60 deposited under accession number ATCC 98621;
- the protein being substantially free from other mammalian proteins.

10. The protein of claim 9, wherein said protein comprises the amino acid sequence of SEQ ID NO:2.

11. A composition comprising the protein of claim 9 and a pharmaceutically acceptable carrier.

12. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:1; and
 - (ab) the nucleotide sequence of the cDNA insert of clone am728_60 deposited under accession number ATCC 98621;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- (b) a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- (ba) SEQ ID NO:1; and
- (bb) the nucleotide sequence of the cDNA insert of clone am728_60 deposited under accession number ATCC 98621;
- (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii);

wherein at least one isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

- (v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:1 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:1; and
 - (w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:1 from nucleotide 179 to nucleotide 4285, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:1 from nucleotide 179 to nucleotide 4285, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:1 from nucleotide 179 to nucleotide 4285.
13. An isolated polynucleotide produced according to the process of claim 12.
14. An isolated polynucleotide comprising the polynucleotide of claim 13.
15. An isolated polynucleotide selected from the group consisting of:
- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 108 to nucleotide 254;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:3 from nucleotide 225 to nucleotide 254;

WO 99/32614	PCT/US98/27140	WO 99/32614	PCT/US98/27140
(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bf377_1 deposited under accession number ATCC 98621;	(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone bf377_1 deposited under accession number ATCC 98621;	(aa) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and	(aa) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and
(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bf377_1 deposited under accession number ATCC 98621;	(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone bf377_1 deposited under accession number ATCC 98621;	(ab) the nucleotide sequence of the cDNA insert of clone bf377_1 deposited under accession number ATCC 98621;	(ab) the nucleotide sequence of the cDNA insert of clone bf377_1 deposited under accession number ATCC 98621;
(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone bf377_1 deposited under accession number ATCC 98621;	(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone bf377_1 deposited under accession number ATCC 98621;	(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);	(ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C; and (iii) isolating the DNA polynucleotides detected with the probe(s);
(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone bf377_1 deposited under accession number ATCC 98621;	(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone bf377_1 deposited under accession number ATCC 98621;	and	(b) a process comprising the steps of:
(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;	(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:4;	(i) preparing one or more polynucleotide primers that	(i) preparing one or more polynucleotide primers that
(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4;	(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:4;	hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:	hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and	(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and	(ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and	(ba) SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3; and
(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).	(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).	(bb) the nucleotide sequence of the cDNA insert of clone bf377_1 deposited under accession number ATCC 98621;	(bb) the nucleotide sequence of the cDNA insert of clone bf377_1 deposited under accession number ATCC 98621;
16. A protein comprising an amino acid sequence selected from the group consisting of:	16. A protein comprising an amino acid sequence selected from the group consisting of:	(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C;	(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C;
(a) the amino acid sequence of SEQ ID NO:4;	(a) the amino acid sequence of SEQ ID NO:4;	(iii) amplifying human DNA sequences; and	(iii) amplifying human DNA sequences; and
(b) fragments of the amino acid sequence of SEQ ID NO:4, each fragment comprising eight consecutive amino acids of SEQ ID NO:4; and	(b) fragments of the amino acid sequence of SEQ ID NO:4, each fragment comprising eight consecutive amino acids of SEQ ID NO:4; and	(iv) isolating the polynucleotide products of step (b)(iii);	(iv) isolating the polynucleotide products of step (b)(iii);
(c) the amino acid sequence encoded by the cDNA insert of clone bf377_1 deposited under accession number ATCC 98621; the protein being substantially free from other mammalian proteins.	(c) the amino acid sequence encoded by the cDNA insert of clone bf377_1 deposited under accession number ATCC 98621; the protein being substantially free from other mammalian proteins.	wherein at least one isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:	wherein at least one isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:
17. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:	17. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:	(v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3;	(v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3, but excluding the poly(A) tail at the 3' end of SEQ ID NO:3;
(a) a process comprising the steps of:	(a) a process comprising the steps of:	(w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 108 to nucleotide 254, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 108 to nucleotide 254, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 108 to nucleotide 254;	(w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 108 to nucleotide 254, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 108 to nucleotide 254, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 108 to nucleotide 254;
(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:	(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:	and	and
(x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 225 to nucleotide 254, and extending contiguously from a	(x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 225 to nucleotide 254, and extending contiguously from a		(x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 225 to nucleotide 254, and extending contiguously from a

nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 225 to nucleotide 254, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 225 to nucleotide 254.

18. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5;
 - (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 426 to nucleotide 569;
 - (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:5 from nucleotide 546 to nucleotide 569;
 - (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone cw354_1 deposited under accession number ATCC 98621;
 - (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone cw354_1 deposited under accession number ATCC 98621;
 - (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone cw354_1 deposited under accession number ATCC 98621;
 - (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone cw354_1 deposited under accession number ATCC 98621;
 - (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:6;
 - (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:6;
 - (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
 - (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).
19. A protein comprising an amino acid sequence selected from the group consisting of:
- (a) the amino acid sequence of SEQ ID NO:6;

(b) fragments of the amino acid sequence of SEQ ID NO:6, each fragment comprising eight consecutive amino acids of SEQ ID NO:6; and

(c) the amino acid sequence encoded by the cDNA insert of clone cw354_1 deposited under accession number ATCC 98621;

the protein being substantially free from other mammalian proteins.

20. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and
 - (ab) the nucleotide sequence of the cDNA insert of clone cw354_1 deposited under accession number ATCC 98621;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
 - and
 - (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5; and
 - (bb) the nucleotide sequence of the cDNA insert of clone cw354_1 deposited under accession number ATCC 98621;
 - (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide products of step (b)(iii);
- wherein at least one isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

- (v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:5, but excluding the poly(A) tail at the 3' end of SEQ ID NO:5;
- (w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 426 to nucleotide 569, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 426 to nucleotide 569, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 426 to nucleotide 569; and
- (x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 546 to nucleotide 569, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:5 from nucleotide 546 to nucleotide 569, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 546 to nucleotide 569.
21. An isolated polynucleotide selected from the group consisting of:
- a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7;
 - a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 151 to nucleotide 891;
 - a polynucleotide comprising the nucleotide sequence of SEQ ID NO:7 from nucleotide 595 to nucleotide 891;
 - a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone nm134_4 deposited under accession number ATCC 98621;
 - a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone nm134_4 deposited under accession number ATCC 98621;
 - a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone nm134_4 deposited under accession number ATCC 98621;
 - a polynucleotide encoding the mature protein encoded by the cDNA insert of clone nm134_4 deposited under accession number ATCC 98621;
 - a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:8;

- a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:8;
 - a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
 - a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).
22. A protein comprising an amino acid sequence selected from the group consisting of:
- the amino acid sequence of SEQ ID NO:8;
 - the amino acid sequence of SEQ ID NO:8 from amino acid 104 to amino acid 163;
 - fragments of the amino acid sequence of SEQ ID NO:8, each fragment comprising eight consecutive amino acids of SEQ ID NO:8; and
 - the amino acid sequence encoded by the cDNA insert of clone nm134_4 deposited under accession number ATCC 98621;
- the protein being substantially free from other mammalian proteins.
23. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:
- a process comprising the steps of:
 - preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and
 - the nucleotide sequence of the cDNA insert of clone nm134_4 deposited under accession number ATCC 98621;
 - hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C; and
 - isolating the DNA polynucleotides detected with the probe(s);
 - a process comprising the steps of:

(i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

(ba) SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7; and

(bb) the nucleotide sequence of the cDNA insert of clone nm134_4 deposited under accession number ATCC 98621;

(ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C;

(iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii);

wherein at least one isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

(v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7, but excluding the poly(A) tail at the 3' end of SEQ ID NO:7;

(w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 151 to nucleotide 891, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 151 to nucleotide 891, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 151 to nucleotide 891; and

(x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 595 to nucleotide 891, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 595 to nucleotide 891, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 595 to nucleotide 891.

24. An isolated polynucleotide selected from the group consisting of:

(a) a polynucleotide comprising the nucleotide sequence of SEQ ID

NO:9;

(b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 1909 to nucleotide 2127;

(c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:9 from nucleotide 2074 to nucleotide 2127;

(d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone yb11_1 deposited under accession number ATCC 98621;

(e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone yb11_1 deposited under accession number ATCC 98621;

(f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone yb11_1 deposited under accession number ATCC 98621;

(g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone yb11_1 deposited under accession number ATCC 98621;

(h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:10;

(i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:10;

(j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and

(k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i).

25. A protein comprising an amino acid sequence selected from the group consisting of:

(a) the amino acid sequence of SEQ ID NO:10;

(b) fragments of the amino acid sequence of SEQ ID NO:10, each fragment comprising eight consecutive amino acids of SEQ ID NO:10; and

(c) the amino acid sequence encoded by the cDNA insert of clone yb11_1 deposited under accession number ATCC 98621;

the protein being substantially free from other mammalian proteins.

26. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

(a) a process comprising the steps of:

(i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:

- (aa) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and
- (ab) the nucleotide sequence of the cDNA insert of clone yb11_1 deposited under accession number ATCC 98621;
- (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C; and
- (iii) isolating the DNA polynucleotides detected with the probe(s);

and

- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9; and
 - (bb) the nucleotide sequence of the cDNA insert of clone yb11_1 deposited under accession number ATCC 98621;
 - (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C;
 - (iii) amplifying human DNA sequences; and
 - (iv) isolating the polynucleotide products of step (b)(iii);

wherein at least one isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

- (v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9, but excluding the poly(A) tail at the 3' end of SEQ ID NO:9;
- (w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 2127, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 1909 to nucleotide 2127, to a nucleotide sequence

corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 1909 to nucleotide 2127; and

- (x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 2074 to nucleotide 2127, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 2074 to nucleotide 2127, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 2074 to nucleotide 2127.

27. An isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11;
- (b) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 1077 to nucleotide 1733;
- (c) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:11 from nucleotide 1158 to nucleotide 1733;
- (d) a polynucleotide comprising the nucleotide sequence of the full-length protein coding sequence of clone ybc2_1 deposited under accession number ATCC 98621;
- (e) a polynucleotide encoding the full-length protein encoded by the cDNA insert of clone ybc2_1 deposited under accession number ATCC 98621;
- (f) a polynucleotide comprising the nucleotide sequence of the mature protein coding sequence of clone ybc2_1 deposited under accession number ATCC 98621;
- (g) a polynucleotide encoding the mature protein encoded by the cDNA insert of clone ybc2_1 deposited under accession number ATCC 98621;
- (h) a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:12;
- (i) a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising eight consecutive amino acids of SEQ ID NO:12;
- (j) a polynucleotide which is an allelic variant of a polynucleotide of (a)-(g) above; and
- (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j).

28. A protein comprising an amino acid sequence selected from the group consisting of:

- (a) the amino acid sequence of SEQ ID NO:12;
 - (b) fragments of the amino acid sequence of SEQ ID NO:12, each fragment comprising eight consecutive amino acids of SEQ ID NO:12; and
 - (c) the amino acid sequence encoded by the cDNA insert of clone *yc2_1* deposited under accession number ATCC 98621;
- the protein being substantially free from other mammalian proteins.


29. A process for producing an isolated polynucleotide, wherein the process is selected from the group consisting of:

- (a) a process comprising the steps of:
 - (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (aa) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and
 - (ab) the nucleotide sequence of the cDNA insert of clone *yc2_1* deposited under accession number ATCC 98621;
 - (ii) hybridizing said probe(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C; and
 - (iii) isolating the DNA polynucleotides detected with the probe(s);
- and
- (b) a process comprising the steps of:
 - (i) preparing one or more polynucleotide primers that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
 - (ba) SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11; and
 - (bb) the nucleotide sequence of the cDNA insert of clone *yc2_1* deposited under accession number ATCC 98621;
 - (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 65 degrees C;
 - (iii) amplifying human DNA sequences; and

(iv) isolating the polynucleotide products of step (b)(iii); wherein at least one isolated polynucleotide comprises a nucleotide sequence selected from the group consisting of:

- (v) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:11 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:11, but excluding the poly(A) tail at the 3' end of SEQ ID NO:11;
- (w) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 1077 to nucleotide 1733, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 1077 to nucleotide 1733, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 1077 to nucleotide 1733; and
- (x) a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:11 from nucleotide 1158 to nucleotide 1733, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:11 from nucleotide 1158 to nucleotide 1733, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:11 from nucleotide 1158 to nucleotide 1733.


FIGURE 1A



Plasmid name: pED6dpc2
Plasmid size: 5374 bp

Comments/References: pED6dpc2 is derived from pED6dpc1 by insertion of a new polylinker to facilitate cDNA cloning. SST cDNAs are cloned between EcoRI and NotI. pED vectors are described in Kaufman et al.(1991), NAR 19: 4485-4490.

FIGURE 1B



Plasmid name: pNOTs
Plasmid size: 4529 bp

Comments/References: pNOTs is a derivative of pMT2 (Kaufman et al,1989, Mol.Cell.Biol.9:1741-1750). DHFR was deleted and a new polylinker was inserted between EcoRI and HpaI. M13 origin of replication was inserted in the ClaI site. SST cDNAs are cloned between EcoRI and NotI

SEQUENCE LISTING

<110> Jacobs, Kenneth
 McCoy, John M.
 LaVallie, Edward R.
 Collins-Racie, Lisa A.
 Evans, Cheryl
 Werberg, David
 Treacy, Maurice
 Agostino, Michael J.
 Steininger II, Robert J.
 Wong, Gordon G.
 Clark, Hilary
 Fechtel, Kim
 Genetics Institute, Inc.

<120> SECRETED PROTEINS AND POLYPEPTIDES ENCODING THEM

<130> 6057A

<140>

<141>

<160> 17

<170> Patent In Ver. 2.0

<210> 1

<211> 4292

<212> DNA

<213> Homo sapiens

<400> 1

ctcaagtttaa acccaacagc cgtatagaaa aggtatgtat caagagattc taaacttca 60
 acccttttc tctatagat agtgaagaa gtagaatatc tcaagtttgc gctgaatc 120
 ctcaacttc acaatttgc ttaacttca ctgttgatc ccggtttgct gttttgatc 180
 ggcacaaatt ggcgttcaac gaactcttc tcttggtcat tctctgaca agttgtgaa 240
 gactacaaa ctgtctggag accttaaaa atgtgtgac ttggaatgtc aagctttaa 300
 aacacagatc tcaagcatga gaaatctatg agaaccttgc tggcgtatcc tgaacttca 360
 caagagaaa gtagaatgtc ttatgttca acttctgaga gaaagggaag attctgtggc 420
 agaaagttaa gaaaggagtt ttgatatc tccagagat gcaagctcaga ttgaaggatc 480
 gtccaatatc gaggaaatc agatgtacac gaagaatct gacttcttc gtctcttgc 540
 agtaagtac aaatttgaac atgaaagatc tgaattaac gttgattatc gtgaaatcc 600
 atactctat gaagagata aagatgaaa atctagtca tatgaagtc attctcagat 660
 agaaccttga ttctatgaa ctatgaaag taacttgttt gaagaccagc ttccagatc 720
 agaggtctct gaagatctgc gaagtcacag tgaatcctga gactgggaag agtaagtgt 780
 tgaagatgt gaacagatc gtatccaga atgtcatgt ccacatctc cagctgtgtc 840
 tggagctaaa gaattgttt gattggag agaacagat gaaagagagc ctcttgaatc 900
 agtatatga cctgtacaaag aaagctcatc tggataga aaatagcag tggaaagaga 960
 gaatgcctca gaaagatna ataatgttga gcttcaaca gaacatcagc aagaatctga 1020
 atcagaatct gattcagtc caaagacaca gtctgaacta gactctgagt cagagacat 1080
 tcccaatctc atctatctg ataaagagc cagcttcca tptacagaaa tatcaacaga 1140
 agatggagat acagggtctg attaaatgc tgaagagac aatccacac taaagatct 1200
 tcccaatctc atctatctg ataaagagc cagcttcca tptacagaaa tatcaacaga 1260
 aaaaagagc acaatcacta atgtatgtc gactctcag ccaagttgtt ttgaatttgc 1320
 ttgttgata ctgctgtctg cataagcga gaaagatna ataatgttgc atgacagaaa 1380
 aaaaagagc gattgtgggg cagatgaca tgaatctct ctcaagagtg aattagacc 1440
 tgaagagaa caagaaatag aagctttaa aattatgaa aagagagatc aattagaaa 1500
 gaacagatc tcaagaaaa cagagatc tgaatctca ccaatttga aagattctc 1560
 gataatttc gaaacccctt gaacttcca gaacttcca aagaaacag aattgtcatt 1620

1

tcccaacag atactgtatc aaataatgt aattgaaat gaagaaatc gaaatttcc 1680
 catgtaatc tatccacagc ataatcaaa agtatatgta ttcaaatgt cacaagctc 1740
 gtcagatgt gtctctaca taaagtacc taagatcag taaagagat taaatgttga 1800
 accctatct tctaaagata gtatgaaaa tcaatgaaa tcaatgaaa ccaagagcc 1860
 tgcctgtgt gaaagagac gattgttga aaatccctg cttaatgtc agatgttctc 1920
 aactgtaac tcttgtct ctcaaatga tatctcagc aagaagagc ctctgtatc 1980
 taaatgtct aaatctat tcaaatga ttttatgat ttcaatgat ctgcatttc 2040
 accaatgtc atcttcaag aaagtgtc gtagacatg gtagagatc ttgagaccga 2100
 tctaatct taagtgttc catgtgtat gttgaaatc gaaagctgtc ttgagattc 2160
 tgcgtcttc ctcttctgt gaaagattc taagcagatc aagatgtgc ttatgttgc 2220
 aagagagaa aagctgtctc taagtcttc tgaatctat gaaagaaaa gtaaatctc 2280
 gtagacagc ttatgtatc aacttgcga tgaatctatc tgcctagaaa aagatgaaa 2340
 gtagacagc tcaatctc aacttgcga tgaatctatc tgcctagaaa aagatgaaa 2400
 tgaatctc caactcagc aagacagaa acagatttc gaaagagc ttgagagaaa 2460
 aagatctc caactcagc aagacagaa acagatttc gaaagagc ttgagagaaa 2520
 ctcaatgata ttcaatgata atgaagagc atgaagata gaaatgaag atgtcttga 2580
 agaaatctc caactcagc aagacagaa acagatttc gaaagagc ttgagagaaa 2640
 agaaatctc caactcagc aagacagaa acagatttc gaaagagc ttgagagaaa 2700
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 2760
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 2820
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 2880
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 2940
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3000
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3060
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3120
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3180
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3240
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3300
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3360
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3420
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3480
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3540
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3600
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3660
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3720
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3780
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3840
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3900
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 3960
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4020
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4080
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4140
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4200
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4260
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4320
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4380
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4440
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4500
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4560
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4620
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4680
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4740
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4800
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4860
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4920
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 4980
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5040
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5100
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5160
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5220
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5280
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5340
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5400
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5460
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5520
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5580
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5640
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5700
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5760
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5820
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5880
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 5940
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6000
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6060
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6120
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6180
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6240
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6300
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6360
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6420
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6480
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6540
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6600
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6660
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6720
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6780
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6840
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6900
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 6960
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7020
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7080
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7140
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7200
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7260
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7320
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7380
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7440
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7500
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7560
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7620
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7680
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7740
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7800
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7860
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7920
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 7980
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8040
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8100
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8160
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8220
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8280
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8340
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8400
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8460
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8520
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8580
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8640
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8700
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8760
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8820
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8880
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 8940
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9000
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9060
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9120
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9180
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9240
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9300
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9360
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9420
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9480
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9540
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9600
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9660
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9720
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9780
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9840
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9900
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 9960
 gaaagagc atgaagatc atgaagatc atgaagatc atgaagatc atgaagatc 10020

<213> Homo sapiens

<400> 2

Met Ala Lys Phe Gly Val His Arg Ile Leu Leu Ala Ile Ser Leu

1

5

10

15

Thr Lys Cys Leu Glu Ser Thr Lys Leu Leu Ala Asp Leu Lys Cys

1

5

10

15

Gly Asp Leu Glu Cys Glu Ala Leu Ile Asn Arg Val Ser Ala Met Arg

1

5

10

15

20

25

30

35

40

45

50

55

60

65

70

75

80

85

90

95

100

105

110

115

120

125

130

135

140

145

150

155

160

165

170

175

180

185

190

195

200

205

210

215

220

225

230

235

240

245

250

255

260

265

270

275

280

285

290

295

300

305

310

315

320

325

330

335

340

345

350

355

360

365

370

375

380

385

390

395

400

405

410

415

420

425

430

435

440

445

450

455

460

465

470

475

480

485

490

495

500

505

510

515

520

525

530

535

540

545

550

555

560

565

570

575

580

585

590

595

600

605

610

615

620

625

630

635

640

645

Asp Tyr Arg Gly Pro 50	Asp Cys Arg Tyr Leu Asn Phe Thr Lys Gly Glu 55 60	Asp Ser Leu Ser Leu Lys Pro Ser Trp Phe Asp Phe Gly Phe Ala Ile 370 375 380
Glu Ile Ser Val Tyr 65	Val Lys Leu Ala Gly Glu Arg Glu Asp Leu Trp 70 75 80	Leu Gly Phe Ala Tyr Ala Lys Glu Asp Lys Ile Met Leu Asp Asp Arg 385 390 395 400
Ala Gly Ser Lys Gly 85	Lys Glu Phe Gly Tyr Phe Pro Arg Asp Ala Val 90 95	Lys Asn Glu Glu Asp Gly Gly Ala Asp Glu His Glu His Pro Leu Thr 405 410 415
Gln Ile Glu Glu Val 100	Phe Ile Ser Glu Glu Ile Gln Met Ser Thr Lys 105 110	Ser Glu Leu Asp Pro Glu Lys Glu Gln Glu Ile Glu Thr Ile Lys Ile 420 425 430
Glu Ser Asp Phe Leu 115	Cys Leu Leu Gly Val Ser Tyr Thr Phe Asp Asn 120 125	Ile Glu Thr Glu Asp Gln Ile Asp Lys Lys Pro Val Ser Glu Lys Thr 435 440 445
Glu Asp Ser Glu Leu 130	Asn Gly Asp Tyr Gly Glu Asn Ile Tyr Pro Tyr 135 140	Asp Glu Ser Asp Thr Ile Pro Tyr Leu Lys Lys Phe Leu Tyr Asn Phe 450 455 460
Glu Glu Asp Lys Asp 145	Glu Lys Ser Ser Ile Tyr Glu Ser Asp Phe Gln 150 155 160	Asp Asn Pro Trp Asn Phe Gln Asn Ile Pro Lys Glu Thr Glu Leu Pro 465 470 475 480
Ile Glu Pro Gly Phe 165	Tyr Ala Thr Tyr Glu Ser Thr Leu Phe Glu Asp 170 175	Phe Pro Lys Gln Ile Leu Asp Gln Asn Asn Val Ile Glu Asn Glu Glu 485 490 495
Gln Val Pro Ala Leu 180	Glu Ala Pro Glu Asp Ile Gly Ser Thr Ser Glu 185 190	Thr Gly Glu Phe Ser Ile Asp Asn Tyr Pro Thr Asp Asn Thr Lys Val 500 505 510
Ser Lys Asp Trp Glu 195	Glu Val Val Val Glu Ser Met Glu Gln Asp Arg 200 205	Met Ile Phe Lys Ser Ser Tyr Ser Leu Ser Asp Met Val Ser Asn Ile 515 520 525
Ile Pro Glu Val His 210	Val Pro Pro Ser Ser Ala Val Ser Gly Val Lys 215 220	Glu Leu Pro Thr Arg Ile His Glu Glu Val Tyr Phe Glu Pro Ser Ser 530 535 540
Glu Trp Phe Gly Leu 225	Gly Gly Glu Gln Ala Glu Glu Lys Ala Phe Glu 230 235 240	Ser Lys Asp Ser Asp Glu Asn Ser Lys Pro Ser Val Asp Thr Glu Gly 545 550 555 560
Ser Val Ile Glu Pro 245	Val Gln Glu Ser Ser Phe Arg Ser Arg Lys Ile 250 255	Pro Ala Leu Val Glu Ile Asp Arg Ser Val Glu Asn Thr Leu Leu Asn 565 570 575
Ala Val Glu Asp Glu 260	Asn Asp Leu Glu Glu Leu Asn Asn Gly Glu Pro 265 270	Ser Gln Met Val Ser Thr Asp Asn Ser Leu Ser Ser Gln Asn Tyr Ile 580 585 590
Gln Thr Glu His Gln 275	Gln Glu Ser Glu Ser Glu Ile Asp Ser Val Pro 280 285	Ser Gln Lys Glu Asp Ala Ser Glu Phe Gln Ile Leu Lys Tyr Leu Phe 595 600 605
Lys Thr Gln Ser Glu 290	Leu Ala Ser Glu Ser Glu His Ile Pro Lys Pro 295 300	Gln Ile Asp Val Tyr Asp Phe Met Asn Ser Ala Phe Ser Pro Ile Val 610 615 620
Gln Ser Thr Gly Trp 305	Phe Gly Gly Gly Phe Thr Ser Tyr Leu Gly Phe 310 315 320	Ile Leu Thr Glu Arg Val Val Ala Ala Leu Pro Glu Gly Met Arg Pro 625 630 635 640
Gly Asp Glu Asp Thr 325	Gly Leu Glu Leu Ile Ala Glu Glu Ser Asn Pro 330 335	Asp Ser Asn Leu Tyr Gly Phe Pro Trp Glu Leu Val Ile Cys Ala Ala 645 650 655
Pro Leu Gln Asp Phe 340	Pro Asn Pro Ile Ser Ser Asp Lys Glu Ala Thr 345 350	Val Val Gly Phe Phe Ala Val Leu Phe Leu Trp Arg Ser Phe Arg 660 665 670
Val Pro Cys Thr Glu 355	Ile Leu Thr Glu Lys Lys Asp Thr Ile Thr Asn 360 365	Ser Val Arg Ser Arg Leu Tyr Val Gly Arg Glu Lys Lys Leu Ala Leu 675 680 685

Met Leu Ser Gly Leu Ile Glu Glu Lys Ser Lys Leu Leu Glu Phe
690 695 700

Ser Leu Val Glu Lys Glu Tyr Glu Gly Tyr Glu Val Glu Ser Ser Leu
705 710 715 720

Lys Asp Ala Ser Phe Glu Lys Glu Ala Thr Glu Ala Glu Ser Leu Glu
725 730 735

Ala Thr Cys Glu Lys Leu Asn Arg Ser Asn Ser Glu Leu Glu Asp Glu
740 745 750

Ile Leu Cys Leu Glu Lys Glu Leu Lys Glu Glu Lys Ser Lys His Ser
755 760 765

Glu Glu Asp Glu Leu Met Ala Asp Ile Ser Lys Arg Ile Glu Ser Leu
770 775 780

Glu Asp Glu Ser Lys Ser Leu Lys Ser Glu Val Ala Glu Ala Lys Met
785 790 795 800

Thr Phe Lys Ile Phe Glu Met Asn Glu Glu Arg Leu Lys Ile Ala Ile
805 810 815

Lys Asp Ala Leu Asn Glu Asn Ser Glu Leu Glu Glu Ser Glu Lys Glu
820 825 830

Leu Leu Glu Glu Ala Glu Val Trp Lys Glu Glu Val Ser Glu Leu Asn
835 840 845

Lys Glu Lys Val Thr Phe Glu Asp Ser Lys Val His Ala Glu Glu Val
850 855 860

Leu Asn Asp Lys Glu Ser His Ile Lys Thr Leu Thr Glu Arg Leu Leu
865 870 875 880

Lys Met Lys Asp Trp Ala Ala Met Leu Glu Glu Asp Ile Thr Asp Asp
885 890 895

Asp Asn Leu Glu Leu Glu Met Asn Ser Glu Ser Glu Asn Gly Ala Tyr
900 905 910

Leu Asp Asn Pro Pro Lys Gly Ala Leu Lys Lys Leu Ile His Ala Ala
915 920 925

Lys Leu Asn Ala Ser Leu Lys Thr Leu Glu Gly Glu Arg Asn Glu Ile
930 935 940

Tyr Ile Glu Leu Ser Glu Val Asp Lys Thr Lys Glu Glu Leu Thr Glu
945 950 955 960

His Ile Lys Asn Leu Glu Thr Glu Glu Ala Ser Leu Glu Ser Glu Asn
965 970 975

Thr His Phe Glu Asn Glu Asn Glu Lys Leu Glu Glu Lys Leu Lys Val
980 985 990

Met Thr Glu Leu Tyr Glu Glu Asn Glu Met Lys Leu His Arg Lys Leu
995 1000 1005

Thr Val Glu Glu Asn Tyr Arg Leu Glu Lys Glu Glu Lys Leu Ser Lys
1010 1015 1020

Val Asp Glu Lys Ile Ser His Ala Thr Glu Glu Leu Glu Thr Tyr Arg
1025 1030 1035 1040

Lys Arg Ala Lys Asp Leu Glu Glu Glu Lys Arg Thr Ile His Ser
1045 1050 1055

Tyr Glu Gly Glu Ile Ile Ser His Glu Lys Lys Ala His Asp Asn Trp
1060 1065 1070

Leu Ala Ala Arg Asn Ala Glu Arg Asn Leu Leu Asn Asp Leu Lys Glu
1075 1080 1085

Asn Ala His Asn Arg Glu Lys Leu Thr Glu Thr Glu Leu Lys Phe Glu
1090 1095 1100

Leu Leu Glu Lys Asp Pro Tyr Ala Leu Asp Val Pro Asn Thr Ala Phe
1105 1110 1115 1120

Gly Arg Gly Ser Arg Gly Pro Gly Asn Pro Leu Asp His Glu Ile Thr
1125 1130 1135

Asn Glu Arg Gly Glu Ser Ser Cys Asp Arg Leu Thr Asp Pro His Arg
1140 1145 1150

Ala Pro Ser Asp Thr Gly Ser Leu Ser Pro Pro Trp Asp Glu Asp Arg
1155 1160 1165

Arg Met Met Phe Pro Pro Gly Glu Ser Tyr Pro Asp Ser Ala Leu
1170 1175 1180

Pro Pro Glu Arg Glu Asn Arg Phe Cys Ser Asn Ser Gly Arg Leu Ser
1185 1190 1195 1200

Gly Pro Ala Glu Leu Arg Ser Phe Asn Met Pro Ser Leu Asp Lys Met
1205 1210 1215

Asp Gly Ser Met Pro Ser Glu Met Glu Ser Ser Arg Asn Asp Thr Lys
1220 1225 1230

Asp Asp Leu Gly Asn Leu Asn Val Pro Asp Ser Ser Leu Pro Ala Glu
1235 1240 1245

Asn Glu Ala Thr Gly Pro Gly Phe Val Pro Pro Leu Ala Pro Ile
1250 1255 1260

Arg Gly Pro Leu Phe Pro Val Asp Ala Arg Gly Pro Phe Leu Arg Arg
1265 1270 1275 1280

Gly Pro Pro Phe Pro Pro Pro Pro Gly Ala Met Phe Gly Ala Ser
1285 1290 1295

Arg Asp Tyr Phe Pro Pro Arg Asp Phe Pro Gly Pro Pro Ala Pro
1300 1305 1310

Phe Ala Met Arg Asn Val Tyr Pro Pro Arg Gly Phe Pro Tyr Leu
1315 1320 1325

Pro Pro Arg Pro Gly Phe Phe Pro Pro Pro His Ser Glu Gly Arg
1330 1335 1340

Ser Glu Phe Pro Ser Gly Leu Ile Pro Pro Ser Asn Glu Pro Ala Thr
1345 1350 1355 1360

Glu His Pro Glu Pro Gln Glu Thr
1365

<210> 3

<211> 412

<212> DNA

<213> Homo sapiens

<400> 3

ttactttatg ccagatcccg tacatgccat tggatcttc tggtaacagg tgggaagct 60
gagcagaa gccctttagt cacttcgga aggcacagct gtaccacatg ggaacgggtt 120
tggcgccg agagacactc atgggcccgg attacgccc cgggcccgtt cctctctgt 180
ctctgtgt cctcacgcca ttggcccac tgcctccac tgcctcgag tccctgtcc 240
cgtctccc tcttgaa cctcagcct cagtaaccc tcagaacgt ggtcgggga 300
agcctctg tggatctg gagcagagt ttgcctgag cc/agattgt gccactgac 360
gcactcagc ctggggcaga gagcagacc ccatctcaa aaaaaaaaaa aa 412

<210> 4

<211> 49

<212> PRT

<213> Homo sapiens

<400> 4

Met Gly Pro Val Leu Leu Gly Arg Arg Ala Leu Met Gly Pro Asp Ser
1 5 10 15

Arg Pro Gly Pro Val Pro Ser Cys Ser Leu Val Leu Leu Thr Pro Leu
20 25 30

Ala Pro Leu Pro Leu Thr Ala Arg Glu Ser Leu Cys Pro Cys Pro Pro
35 40 45

Ser

<210> 5

<211> 1317

<212> DNA

<213> Homo sapiens

<400> 5

gtctggaga gtcaattcag gggaaagata caagattgat ttgtanaacc ctgaaatgt 60
agatttcttg tagatgcatc ctccagcttg taatatgtt ttgtagagtg aagccatggg 120
aagccatgtg taacagagct tagactcca aaactaatca atgtcaggt ggcataatc 180
ctagcccttt acatgtaac ctgtctgcaa aattagcttt tttaaaaa aaaaaaaaaa 240
aaatttgggg ggttcaattt acatccaga aactctgcat ttcaaaaat tcagtgcaag 300
cgccagcaga ttgtgtctta aggtacgat ttgnaacct atgggcagtg taacaaatat 360
gaacaaactg ttccacact tgcactgat caagcagagt gctctccat ttgtttgca 420
gagaaatgtt ttcaattcc cgtgtgttc cattctctc tgaatttcg atttactca 480
ttttttaa gctctctt atcccttcc ttcaagcact gtgtcatgg caactttcta 540
taacctttc attctatgt acagtagagt aaattgacg tgaatgacg taacctactt 600

gtttgataa attattgaaa tccattgca cctgtaga atggacttaa aagtactgct 660
ggaacggcat gtgtgtcaa agtacattga ttgtcaaat ataggaat ggcacaatga 720
acgtgtgtt ggggggggaa agggaaaca ggttagtca gatgtaatt tcatgtgtg 780
taataaat gttaaaaca aaaaaattg ttattttct ttctctcgg tgaatgaca 840
ttagcatgtg aactactctg ggaattctta tcgaactgt tctgttga tatttactat 900
taatgaaat aattctttaa gggaggtttt gttanaacg tattaacagg aaattgtgta 960
tgagatatt aatgaataa gnaattcaac aagaatgatt aagctactc caaagtgtt 1020
gtcaattgtt aaacctgtt ttactgtct tgcattatg acatttcatt tgaagagatg 1140
tttgtgtgt agctaaactgt tcaagtctgg tgcagactgc tgtctctagg catcacaaa 1140
cgctaaattt gtgtaattgg agctctcgc tgtatctgg aaatgacagg aagcgcgcg 1200
tttgtatatt gttcttcaa gtatattaa ataaaaaag aaactattgc tactaaaaa 1260
aaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1317

<210> 6

<211> 48

<212> PRT

<213> Homo sapiens

<400> 6

Met Phe Phe Ile Ser Arg Val Phe Phe Pro Phe Pro Ser Glu Ile Leu Ile
1 5 10 15

Leu Ser Ile Phe Leu Arg Leu Leu Phe Ile Ser Phe Leu Lys Ala Leu
20 25 30

Leu Leu Trp His Phe Ser Ile Thr Phe Ser Phe Phe Leu Cys Thr Val Ala
35 40 45

<210> 7

<211> 1442

<212> DNA

<213> Homo sapiens

<400> 7

tgcggtgttt ttctctctt ccgtgcaacg ctggcaagtc tcaagtcgc cacagaasaa 60
tgccctgat tcaagtctc tgcctagctg taactgtta atcagaacta cctggcatct 120
tctgaacaa gacttcaat agggccagct atgcttgct tcaaccagaa gttttctcaa 180
gcatttcaa agatactgaa gtacttttc ccagtgggac taagaacagg cagacagat 240
atacttttc tcaagatgc tctccagena aactttccc catgtccaa gcttggtgtt 300
tctctcat ttccagcgtc tatgagcag acacagtcgt atcatatc ccttcgcgcg 360
tttaaaagc agcagaagca agcacttca gccagacct caagcaccat cacttacta 420
actgacgcc caaagcagc attatgta actcggcag gactaatccc cttegttgt 480
ccaccatgg tcatctgat gacaaaact tatattcca tattagcttt tactcagatg 540
gcttatggag ccagtttctt atctttctg ggttgatca gatggggtt tgcctacca 600
gaagctagtc cagcnaacc agactacct aattagcta gcagtgcag tctcttttc 660
tttctatgt ttgtctctt tattttgaa agacttagt aagccatgt cacagaata 720
atggtcatgg gtagtagcat tcaacttga cttttctt taccacatta tcccactga 780
tttaagccc tgaagatagt agtcaetta ttggccact tttaatttat aatacetta 840
gtatttaaa tagtttttc agaaaaggc caaagagac ctggcaggt ataaaaata 900
taaaagctcg ggaagtggag agcaactctg ccagctgtc gccctctcg ggaagtggag 960
agcctctcg cctggcccgc tgaactatcg ggaagtgga caagccttc tgcceggcg 1020
ctgcaaac tcccagct gaagtacag cctgttgt gtattttt gtcttctca 1080
agtttgcat ttcgacata agtttact tttagtaaa agttttaaa atataatat 1140
ataatacac tgaataaac attgtatgc cagctaccc ttittctact tctgtttgce 1200
ttttttcc cacacaaag tgaatttacc ttacagatt gtcttctact tctagaatt 1260
gttacttcat ggttaattact tgaacaaag ctggaatc cctgacaagt actttctcat 1320

tcacagatata ttagatttca ctacagtcact tbatgaataa tatagttatc cacttaanaa 1380
 ttccaaattt ttacacactc tgaataataa agatataaaa tcccttaaa aaaaaaaaaa 1440
 aa 1442

<210> 8
 <211> 247
 <212> PRT
 <213> Homo sapiens

<400> 8
 Met Leu Arg Phe Ile Gln Lys Phe Ser Gln Ala Ser Ser Lys Ile Leu
 1 5 10 15

Lys Tyr Ser Phe Pro Val Gly Leu Arg Thr Ser Arg Thr Asp Ile Leu
 20 25 30

Ser Leu Lys Met Ser Leu Gln Asn Phe Ser Pro Cys Pro Arg Pro
 35 40 45

Trp Leu Ser Ser Ser Phe Pro Ala Tyr Met Ser Lys Thr Gln Cys Tyr
 50 55 60

His Thr Ser Pro Cys Ser Phe Lys Lys Gln Gln Lys Gln Ala Leu Leu
 65 70 75 80

Ala Arg Pro Ser Ser Thr Ile Thr Tyr Leu Thr Asp Ser Pro Lys Pro
 85 90 95

Ala Leu Cys Val Thr Leu Ala Gly Leu Ile Pro Phe Val Ala Pro Pro
 100 105 110

Leu Val Met Leu Met Thr Lys Thr Tyr Ile Pro Ile Leu Ala Phe Thr
 115 120 125

Gln Met Ala Tyr Gly Ala Ser Phe Leu Ser Phe Leu Gly Gly Ile Arg
 130 135 140

Trp Gly Phe Ala Leu Pro Gln Gly Ser Pro Ala Lys Pro Asp Tyr Leu
 145 150 155 160

Asn Leu Ala Ser Ser Ala Ala Pro Leu Phe Phe Ser Trp Phe Ala Phe
 165 170 175

Leu Ile Ser Gln Arg Leu Ser Gln Ala Ile Val Thr Val Ile Met Gly
 180 185 190

Met Gly Val Ala Phe His Leu Gln Leu Phe Leu Leu Pro His Tyr Pro
 195 200 205

Asn Trp Phe Lys Ala Leu Arg Ile Val Val Thr Leu Leu Ala Thr Phe
 210 215 220

Ser Phe Ile Ile Thr Leu Val Val Lys Ser Ser Phe Pro Gln Lys Gly
 225 230 235 240

His Lys Arg Pro Gly Gln Val
 245

<210> 9

<211> 2696
 <212> DNA
 <213> Homo sapiens

<400> 9

taggcctctc tggcgcgtga gctgtccccc ctatgttggga atgtcaacc ttctgttctc 60
 aggttatag ggggggcaga gacagtcctg ctggagaga tgcacagctc gggatctggc 120
 cagtcctcgg ggcagagact gcaagagctc ggtacacact ggtgtgtgat ctctgtatgc 180
 tttagatcat ggcacatgag gtcctctgtg tgaatcat gattcatttc tgggtgtctc 240
 ctggcaccac ctatagatct cacagagac agttccctag agtttacttc ctgtgacac 300
 aaggagagac gtaccctctg tgaatctca atgattctt ccttgaaggt cactttgtgt 360
 atactcagtg aaggttact tccgttgtat cctagagtc agctcctgg atgtcatatg 420
 gctgaagcat gtactctctg tatggacag tgaacagct ctgaactggc ttctccctcc 480
 aaacctctct ttgtgtgtg tggcctcggg gttcttccca ggaagagaa aagcaccggs 540
 acctgtgacc aatctgtagg accttaacgg aaaaaacaa atattgtac gttcaatccc 600
 attcaaacac gtcaatctg cgaactcggc ctggagagg agtttggga tgaacctagt 660
 gcaaacactc gttaaagac tcccttccca ccccttctct ttgttgtac gctgtgtct 720
 gctgtgtctt gttcatctga atcgtgtcag ccaagtgtgt gttgtctctg tcaagccagt 780
 atggcagagt gttaggttca gtatggcata gtatggctcc ttgggcaga atgtctcgtg 840
 tggctcgtga ggttagatg gtttgggtgc ttccaccag ctggacatct tgggtatgt 900
 ctgatgtatc agaatgtctt ggtgtgtcca ccaaggtctc tgaagaacta gaattctcg 960
 atgagatctg acaagccagg cggctctgag agttgttga ggaatgtgtc ctatagttct 1020
 gtgtcgttgg tcaagcccaa ggaacttgg gcaagtatg attttagggc ctgacaacca 1080
 tgaagactag gatagcttag acctctctc acctccacc atctccctct ctctcttga 1140
 gacacactcc accttctcca acccaagca gggcgccagg tgccttggat ccatatcatg 1200
 catctctggg gggggggcgc cccatggcca ccccttcccc catltgtccg ctctctatgt 1260
 ctctcaaac ctittctct ctatgacttc gggggaatc cagctctctc gtctctctcc 1320
 taaaaaagg gggagagaaa gcaacagaa caattcttc cctataagcc tatggatagc 1380
 ctctccctgt cttagagagc accccaatat caaatgttga aatctcttag taagcatag 1440
 cctctagagt accttgact gaattccca ccccaagctc tccaccaggt gggagagctc 1500
 aacttgggca ctgggtgtac ttittcaatg ccttgtcat ctccaggttg ggaagcaggc 1560
 cccacttccc ctgccctata cccacttccc catgttgtgt gcccaacccc taactccagg 1620
 actgaacca gatgtatc tgaatgcmaa aacattctc gatgtaatc tgtatcatc 1680
 tctctacac gttgggggtc ctgggttga ggggtgggtg cggctctgtg ggcacttgc 1740
 cccctcaccg tctcaaaa ccttcaagta tttaacaga tcttaccag cagcggagta 1800
 ttacagtatc taagtgtgat atccccttaa agccccccg gacctataga ggaagggag 1860
 gacagagga gattgaagta agttctgga ctgggtgagt ggaactatgt gaactcatt 1920
 gaatacatc cgaactccc gttggcagc cgtttctcc aaacctatc acttgaattc 1980
 ggttcccaat cagcgggtc caggactct ctcaacaga caactctcg gggctgggct 2040
 ctctcgaana gttgttgtc ttgtgtctg tgaacaa ccttccatc catattctc 2100
 gggggacccc taccagaca gccaggttga tctgaaggt atacttgtc agtcaattga 2160
 gctagtcaac tcaatagtt gttgagcag gaggcacac ttctcccat ttacttggg 2220
 aaactcaat caccattct gccattctt gaagttctc tctgaactc gaccacac 2280
 ttctgtctg cagtttgtc agaggggaca caaatgttgg gtcagagat agattatg 2340
 aaaaaccaa catctctt ttcttccc gttcccat tagcacaac gttctcagg 2400
 tctctagtg gctccttg acctctctc cagacacag taggtctta ataaagtct 2460
 gctgattga atataccc tatctctc catltgtc ctatgtccc atactctcc 2520
 caagtctc cctcccttc ttgtctcgg tccctatgac ttctcatlt ttcttctcc 2580
 gttgtgttc catgttttc tgtctgtc ctatcttag ctltgtctc ctctctctc 2640
 tctcaaatg tctactct ctctcccaa ttcccatc taaaaaaa aaaaaa 2696

<210> 10
 <211> 73
 <212> PRT
 <213> Homo sapiens

<400> 10
 Met Asn Ser Phe Ala Tyr His Ser His Pro Pro Leu Gly Ser Arg Phe
 1 5 10 15

agtggtctg tgaagtcctc tagcgggggc ttactctgg ccggcgaca ggggcgggcc 2520
 cggggggcc tgactacca ggaagccga gtggccttct ccccccaac accgattccg 2580
 gcaatgaga cgtggtctg tccacgttc gccggaact ttccatgcc cagactccag 2640
 tcaagtga cgcaggttg ggagagtcg gccctggga tcttctctt gactctttt 2700
 attttatca tggactagt cgtctcctt gtccaccca ataaaagggt cttctctaaa 2760
 aaaaaaaaa aaaaaaaaa aaaaaaaaa a

<210> 12
 <211> 219
 <212> PRT
 <213> Homo sapiens

<400> 12
 Met Ser Pro Gly Trp Ile Arg Leu Pro Thr Ser Ser Gln Thr Glu Ile 15
 1 5 10

Leu Met Leu Pro Val Leu Ser Ala Thr Leu Gln Val Arg Thr Ser Cys 30
 20 25

Pro Ser Phe Val Leu Val Thr Arg Pro Val Ser Ser Thr Met Lys Ile 45
 35 40

Arg Phe Arg Phe Leu Ser Pro Gly Leu Ile Ser Phe Thr Lys Val Ser 60
 50 55

Val Val Met Leu Pro Glu Pro Arg His Pro Thr Gly Trp Gly Ile Glu 80
 65 70 75

Asp Glu Gly Ser Met Leu Gly Ser Phe Ala Pro Met Leu His Phe Pro 95
 85 90

Arg Pro Thr Tyr Pro Ile Arg Met Gly Ser Gly Ser Leu Asn Pro Ser 110
 100 105

Asn Pro Ser Lys Arg Leu Lys Lys Asn Ile Pro Gly Gly Leu Gln Leu 125
 115 120

Gln Asp Gln Asn Leu Gly Val Ser Gly Gln Ala Ala Leu Gly Leu Glu 140
 130 135

Gly Pro Leu Pro Gly Cys Ser Phe Ser Leu Lys Pro Arg Ser Gly Gly 160
 145 150 155

Ala Asp Val Asp Arg Gly Arg Glu Pro Gly Ala Gln Pro Gly Ser Arg 175
 165 170

Ile Leu Leu Ala Arg Ser Ser Gly Thr Leu Ile Pro Thr Ser Arg Asp 190
 180 185

Ser Val His Pro Leu Pro Tyr Arg Gln Pro Thr Thr His Pro Ser Gln 205
 195 200

Pro Ala Gly Leu Cys Arg Gly Tyr Lys Leu Leu 215
 210

Leu Gln Thr His Ser Leu Glu Ser Gly Ser Gln Ser Ala Gly Ser Arg 30
 20 25
 Thr Pro Leu Thr Gln Thr His Leu Arg Arg Leu Gly Leu Leu Lys Ser 45
 35 40
 Val Cys Leu Gly Cys Leu Cys Asn Asn Pro Ser Leu Phe Ile Phe Leu 60
 50 55

Gly Asp Pro Leu Pro Ser Gln Pro Gly 70
 65

<210> 11
 <211> 2791
 <212> DNA
 <213> Homo sapiens

<400> 11
 tttttttaga gtgtaaatc ttattaggaa ggaagactt cagttagact cccatgtctc 60
 acacagaaga aacagatgtc aactgcactt tctctcttc tttcttctt tttttttg 120
 agatgagtt tgcctctat tgcacggtt ggaatgcaat tttctcaact cggctcaact 180
 caactctgc ctcctggtt caagagatc tctgtctca gctctcaag tagctgggat 240
 taacagcata cgcacactg cctgactat tctgtatatt tagtagaac ggggtttctc 300
 catgtgttc aggtctgctt tgaactcgc actcaggtt atccgccac ctgagttctc 360
 caaagtgtc ggaatatac cgtagtcac tgcgccacg cagtaactc cattctaaa 420
 gaggaaagag agcagcgga ggtctctgc tccacaggga caggtagctc agctggaca 480
 tgaggagta tgagattag gtgataag acactgtcca ccaactcca ctgaattca 540
 gtgcttaaa tactgtaca cagcacaac agtgaagac tatctgtc tccagggac 600
 acttggaag tggttggcg caggaagaa gaatgtcat ctatcttg ctgtctctc 660
 gggttcttt gccctacta acaggtttc tgaagggcc aggcggcct cagagtgct 720
 ggttggctg attggagtc tgggtggat ggaaggata tgaagggat 780
 gtgggcacc accggactt ggtgggac tsagtccat cccattctg ttctcagag 840
 ctggaaggg agcagaggtt cagtgtag ctgggaagc tgaaggttg ctgtctctc 900
 gacccctct gttgggtcc tgcgtgtc tgaactctg gttgtctca ctgaattag 960
 gaactcaga ataaacata cagaattct caatctctg cagatcacc ccaaggccag 1020
 tatatagt cagacactt tgaanaact agcgtacc ttgtgtgag cggataagt 1080
 cccaggtc gatacagtt ccaacatc ccaagaca gatattgt ctgctggtt 1140
 tgcgcacc ttgtcagtc cgaactcat gccgtctt ttgttgtc actcggctg 1200
 tctccagac aaagaata aggttcagt tcttgagcc aggttgata tcttcaca 1260
 aggtctcgt cgtcagctg ctgagctc ggcacccac tggatggga atagaggtg 1320
 aaggtcact gcttgatcc ttgcccaca tgtctcact ccaaggctt acctaccaca 1380
 ttaggatgg gtcaggcgc etcaacct ctacacct taaaagatta aaaaagaca 1440
 tcccggag cctcaact caggataga attgggggt ccttgagag gctgtcttg 1500
 ggtggaag cccctctcg gtagctct ttagtctaa gcgcgaat ggcggagcg 1560
 acgtagacag ggttaggaa cccgtgac agcaggag tagaatcta ctggccagat 1620
 ctccggac cctacccg acagcggg actcgctca tctctccc taccggcgc 1680
 cccacaca ccaacagc cggcagag tggccgtg ctggaatta tctgagcg 1740
 ggcgtaaga agcggtct gatggcgcg gtgaggtg aggcggcgc cgaaggcgc 1800
 acggagaaa cagaagtg cagatttt gaagagctg ctgttaca caaaagaa 1860
 tttagtga ttacgtgg actcgttg caagctcg aaccgagc cctcagtta 1920
 cctgcctacc cggagatcc cgtcgaaca gatcagtg acagaaaga caaacatct 1980
 cctgcctac ctgcacagc aatggaca aaagaacgt gcaagaaga gagaccagga 2040
 gcaagtgg atagagtc agactcgc actccctcg aagttggcg ggaaccagac 2100
 cccagatg cagagagca cttaagact tcaactcac aggcgcttc tgcaggtct 2160
 gctctcgtt cgcacatg ctgcgcgc atgttaag acccgcgc cccgctccc 2220
 tgcggccca tccacactt ggtccacac ctctccaac ctataggag ccatgtatt 2280
 tatttctct gattttat ttatcgta actgtata agcgttggtt aaaggggaca 2340
 tcaagccag tagtgatg ttgagatg cttctaaa aaacacat tgcctccc 2400
 accccgct tccatgggc cagttccc attctgcc cagttctc agagaccag 2460

<210> 12
 <211> 219
 <212> PRT
 <213> Homo sapiens

<400> 12
 Met Ser Pro Gly Trp Ile Arg Leu Pro Thr Ser Ser Gln Thr Glu Ile 15
 1 5 10

Leu Met Leu Pro Val Leu Ser Ala Thr Leu Gln Val Arg Thr Ser Cys 30
 20 25

Pro Ser Phe Val Leu Val Thr Arg Pro Val Ser Ser Thr Met Lys Ile 45
 35 40

Arg Phe Arg Phe Leu Ser Pro Gly Leu Ile Ser Phe Thr Lys Val Ser 60
 50 55

Val Val Met Leu Pro Glu Pro Arg His Pro Thr Gly Trp Gly Ile Glu 80
 65 70 75

Asp Glu Gly Ser Met Leu Gly Ser Phe Ala Pro Met Leu His Phe Pro 95
 85 90

Arg Pro Thr Tyr Pro Ile Arg Met Gly Ser Gly Ser Leu Asn Pro Ser 110
 100 105

Asn Pro Ser Lys Arg Leu Lys Lys Asn Ile Pro Gly Gly Leu Gln Leu 125
 115 120

Gln Asp Gln Asn Leu Gly Val Ser Gly Gln Ala Ala Leu Gly Leu Glu 140
 130 135

Gly Pro Leu Pro Gly Cys Ser Phe Ser Leu Lys Pro Arg Ser Gly Gly 160
 145 150 155

Ala Asp Val Asp Arg Gly Arg Glu Pro Gly Ala Gln Pro Gly Ser Arg 175
 165 170

Ile Leu Leu Ala Arg Ser Ser Gly Thr Leu Ile Pro Thr Ser Arg Asp 190
 180 185

Ser Val His Pro Leu Pro Tyr Arg Gln Pro Thr Thr His Pro Ser Gln 205
 195 200

Pro Ala Gly Leu Cys Arg Gly Tyr Lys Leu Leu 215
 210

<220>
<223> oligonucleotide
<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue
<<400> 13
cnaatgttc aggtctgaga gatctcagc
<210> 14
<211> 29
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide
<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue
<<400> 14
tnagaagga atgaacac accggaat
<210> 15
<211> 29
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide
<220>
<221> misc_feature
<222> (2)
<223> biotinylated phosphoramidite residue
<<400> 15
tnagcagac cagtgctgga gcaacgaag
<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence
<220>
<223> oligonucleotide
<<400> 16
ggctatggaa gccatgggc
<210> 17
<211> 18
<212> DNA
<213> Artificial Sequence

29

29

29

20

<220>
<223> oligonucleotide
<400> 17
gtctgggacg atgctggc

18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/27140

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 15/00, 15/12
US CL : 435/69.1, 320.1, 325; 536/23.5, 23.1, 24.31; 530/350
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 320.1, 325; 536/23.5, 23.1, 24.31; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Genbank, Geneseq, Embi-EST, Swissprot
search: SEQ ID No. 1 and 2

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HECKEL, D. et al. cDNA cloning and chromosomal mapping of a predicted -coil proline-rich protein immunogenic in meningioma patients. Human Molecular Genetics. 06 November 1997, Vol. 6, No.12, pages 2031-2041, especially Figure 2.	1-7, 9-14
X	Database Genbank, US National Library of Medicine, (Bethesda, MD, USA), Accession Number U73582, HECKEL, D. et al. Human meningioma-expressed antigen 11 (MEA11) mRNA. 19 November 1997.	1-7, 9-14
X	Database Genbank, US National Library of Medicine, (Bethesda, MD, USA), Accession Number Q59861, ADAMS, M.D. et al. Human brain Expressed Sequence Tag EST 00768. Geneseq. 16 March 1994.	1-7, 9-14

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

- * Special categories of cited documents:
- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 - *X* document of particular relevance; the claimed invention cannot be considered novel or non-obvious in view of the disclosure in the document to which the document is taken alone
 - *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
 - *A* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
15 FEBRUARY 1999	02 MAR 1999
Name and mailing address of the ISA/RUS Communication of Patent and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer: <i>ELIANE LAR-WESLEY</i> Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/27140

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database Genbank, US National Library of Medicine, (Bethesda, MD, USA), Accession Number AA446039, HILLIER, L. et al., WashU-Merck EST Project 1997, 03 June 1997.	1-7, 9-14
X	Database Genbank, US National Library of Medicine, (Bethesda, MD, USA), Accession Number AA135566, HILLIER, L. et al., The WashU-Merck EST project. 30 November 1996.	1-7, 9-14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/27140

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-14, drawn to an isolated polynucleotide having SEQ ID No:1, a protein having SEQ ID No:2 encoded by the cDNA insert of clone am728_60, a process for producing a protein and a process for producing an isolated polynucleotide.

Group II, claims 15-17, drawn to an isolated polynucleotide having SEQ ID No:3, a protein having SEQ ID No:4 encoded by the cDNA insert of clone bG77_1, and a process for producing an isolated polynucleotide.

Group III, claims 18-20, drawn to an isolated polynucleotide having SEQ ID No:5, a protein having SEQ ID No:6 encoded by the cDNA insert of clone cw354_1, and a process for producing an isolated polynucleotide.

Group IV, claims 21-23, drawn to an isolated polynucleotide having SEQ ID No:7, a protein having SEQ ID No:8 encoded by the cDNA insert of clone nm134_4, and a process for producing an isolated polynucleotide.

Group V, claims 24-26, drawn to an isolated polynucleotide having SEQ ID No:9, a protein having SEQ ID No:10 encoded by the cDNA insert of clone yb11_1, and a process for producing an isolated polynucleotide.

Group VI, claims 27-29, drawn to an isolated polynucleotide having SEQ ID No:11, a protein having SEQ ID No:12 encoded by the cDNA insert of clone yec2_1, and a process for producing an isolated polynucleotide.

The inventions listed as Groups I-VI do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reason: the special technical feature of Group I is the nucleotide sequence having SEQ ID No:1, the protein having SEQ ID No:2 and a method of making a protein and an isolated polynucleotide. Groups II-VI do not share the technical features of Group I because the claims are to different nucleotide sequences and proteins.